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ABSTRACT 
Anti-angiogenic therapies aimed at halting new blood vessel formation are now being 
extensively studied as inhibitors of excessive angiogenesis. Conversely, compounds with ability 
to stimulate angiogenesis are being considered as a therapeutic approach for insufficient 
angiogenesis. Food-borne bioactive compounds such as genistein, resveratrol, curcumin, the 
Bowman-Birk inhibitor, and catechins are being potentially established as good candidates for 
angioprevention.  
The aim of our study was to determine the anti-or pro-angiogenic activity of  milk-based 
sphingolipids such as C6-ceramide (Cer), Sphingomyelin (SPM) and Glucosylceramide 
(GluCer), in vitro, using breast cancer (MCF-7), colon cancer (Caco-2) and prostate cancer (DU-
145) cell-lines, on angiogenic factors such as vascular endothelial growth factor (VEGF), 
cathepsin-D and hypoxia inducing factor-1alpha (HIF-1α) expression and cell migration under 
normoxia and hypoxia.   Another aim was to conduct an in vivo study using chorioallantoic 
membrane (CAM) and zebrafish model system to substantiate the in vitro results. 
Breast cancer cells (MCF-7) treated with SPM had reduced cell migration under hypoxic 
conditions. Cathepsin-D expression under SPM treated MCF-7 cells was significantly lower 
under both conditions. GlcCer had significant apoptotic activity under hypoxic MCF-7 cells. 
Colon cancer cells (Caco-2) treated with Cer had reduced cell growth at > 50 μM under 
normoxic as well as hypoxic conditions. Cathepsin-D, cell migration and HIF-1α expression 
were significantly reduced under hypoxic condition. SPM had low cathepsin-D levels and cell 
migrations in normoxic and hypoxic conditions as well as low HIF-1α at hypoxic condition. In 
GlcCer treated cells, the levels of cathepsin-D and cell migration were reduced under normoxic 
and hypoxic conditions. 
Prostate cancer cells (DU-145) exposed to SPM had reduced cell viability. All the 
 ix
compounds had lower levels of VEGF expression at normoxic conditions at 50 μM exposure; 
only GlcCer had lower VEGF expression under hypoxic condition. The cell migration was 
reduced under normoxic condition and also for cells exposed to Cer under hypoxic condition.  In 
vivo results showed ceramide was anti-angiogenic as confirmed by both CAM assay as well as 
zebrafish model. SPM proved to facilitate sprouting, however, the blood vessels looked dilated. 
GlcCer disrupted the neovascularization in CAM model and restricted the ISV formation in 
zebrafish. 
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CHAPTER 1.  INTRODUCTION 
There are more than eighty chronic degenerative diseases characterized by the 
uncontrolled growth of new capillaries. These are known as “angiogenic diseases”. Angiogenesis 
is the formation of new blood vessels from preexisting ones. Unlike physiological angiogenesis 
which is tightly controlled and important for embryonic development and wound healing, 
pathological angiogenesis is uncontrolled and may be excessive or insufficient. Diseases in 
which it would be useful to inhibit excessive angiogenesis include chronic inflammation, solid 
and hematological malignancies, diabetes and age-related vision loss, diabetes-related kidney 
complications, HIV and AIDS, multiple sclerosis, rheumatoid arthritis, obesity, and many others. 
Pro-angiogenic compounds are useful for human diseases that are associated with insufficient 
angiogenesis such as ischemia/reperfusion, diabetic delayed wound healing, cardiovascular 
diseases, and many others. Anti-angiogenic therapies aimed at halting new blood vessel 
formation are now being extensively studied as inhibitors of excessive angiogenesis (Folkman 
and Kalluri, 2004; Carmeliet, 2004; Cao et al., 2005; Cline et al., 2002). Conversely, compounds 
with ability to stimulate angiogenesis are being considered as therapeutic approach for 
insufficient angiogenesis. Food-borne bioactive compounds such as genistein, resveratrol, 
curcumin, the Bowman-Birk inhibitor, and catechins are being potentially established as good 
candidates for angioprevention (Cao et al., 2002; Shao et al., 2002; Losso, 2002; Fotsis et al., 
1993).  
The uniqueness of milk fat lies in its content of several highly desirable biologically 
active compounds having considerable potential for use in the food and pharmaceutical 
industries, particularly relative to developments in the area of angiogenesis. Milkfat contains 
ceramides, sphingosine, sphingomyelin, and short chain fatty acids. These bioactive compounds 
are not required for growth but have been identified as health enhancing in models of 
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carcinogenesis and cell cultures (Vesper et al., 1999). Sphingosine-1-phosphate, a biosynthetic 
product of sphingosine phosphorylation may be pro-angiogenic.  
We hypothesize that milkfat sphingolipids or their metabolites may modulate 
pathological angiogenesis. We propose to bring our experience in the screening of anti- or pro-
angiogenic functional foods to the study of angiogenic differentiation of milkfat sphingolipids 
and sphingosine-1-phosphate in the context of the specific aims: (1) determination of the anti-or 
pro-angiogenic activity of sphingolipids such as C6-ceramide (Cer), Sphingomyelin (SPM) and 
Glucosylceramide (GluCer), in vitro, using  breast cancer (MCF-7), colon cancer (Caco-2) and 
prostate cancer (DU-145) cell-lines in absence or presence of stimulators of angiogenesis, (2) 
conduct an in vivo study using chorioallantoic membrane (CAM) assay in chick embryo and a 
zebrafish model system to substantiate the in vitro results. 
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CHAPTER 2.  LITERATURE REVIEW 
2.1 Characteristics of Normal Cells 
Normal cells live in complete harmony with their existing environment, undergoing 
communication with the neighboring cells, repair and replacement of tissues, and other aspects 
of cell behavior. The cells interact either directly, via cell-to-cell contact, or indirectly by 
exchange of messenger compounds such as hormones and growth factors. The cells 
communicate and respond to the neighboring cells with the help of cell adhesion molecules such 
as cadherins and/or through cell-to-cell portals called gap junctions. This process helps cells to 
respond to external stimuli and undergo either a programmed cell death called apoptosis, 
proliferate if new cells are needed, or stop cell-division (Hanahan and Weinberg, 2000; Boik, 
2001). Cells participate in a series of events involving cell division called mitosis where cells 
divide and share one-half of each chromosome with the offspring. The cycle consists of four 
phases, namely, gap phase (G1), synthesis phase (S), second gap phase (G2), and mitotic phase 
(M). The process of cell division and cell cycle is tightly regulated in normal cells. 
2.2 Characteristics of Cancer Cells 
Cancer cells enter the normal cell cycle except that the stimulation is in excess.  The process 
of over-expression of the stimuli leads to abnormal production of growth factors, the binding of 
growth-factors to their receptors, abnormal signal transduction, and abnormal production or 
activity of transcription factors. Cancer in humans can be caused by specific chemicals or 
mixture of chemicals (cigarette smoke, various therapeutic agents, diet, the workplace, and the 
general environment), radiation (both ultraviolet and ion radiation), viruses (hepatitis B, Epstei-
Barr, papilloma, and certain retroviruses), and oxidative damage to DNA due to endogenous 
metabolic reactions. Carcinogenesis involves complex interactions between several factors, both 
exogenous (environmental) and endogenous (genetic, hormonal, immunologic, etc.).  The stages 
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are mainly divided into initiation, promotion (appearance of benign tumors), and progression (the 
conversion of benign to malignant tumors). The common events that play a major role in 
induction of carcinogenesis can be clustered under six pro-cancer events as described by 
Hanahan and Weinberg (2000). These events serve as the hot spots for cancer treatment. The 
following are the events and descriptions: 
2.2.1 Self-sufficiency in Growth Signals 
Mitogenic growth signals (GS) are required by normal cells before they move from the 
quiescent state into active proliferative state. Tumor cells generate many of their own growth 
signals, thereby reducing their dependence on stimulation from normal tissue microenvironment 
by acquiring GS autonomy. The common molecular strategies for achieving autonomy are the 
alteration of extracellular growth signals such as platelet-derived growth factor (PDGF) and 
tumor growth factor (TGFα); transcellular transducers of those signals are mitogenic growth 
factor (GF) receptors. Epidermal growth factor receptor (EGR-R/erbB) and extracellular matrix 
receptors (integrins) are some of the cell surface growth receptors that stimulate progrowth 
signals; and intracellular pathways that translate those signals into action.  
2.2.2 Insensitivity to Anti-growth Signals 
Anti-growth signals in normal cells can block proliferation by two distinct mechanisms. 
The cells may be forced out of the active proliferative cycle into the quiescent (G0) state or be 
induced to permanently relinquish their proliferative potential by being induced to enter post-
mitotic states. Cancer cells evade the anti-proliferative signals by avoiding the cytostatic 
antigrowth signals. Most of the anti-proliferative signals are regulated through the retinoblastoma 
protein (pRb), which is disrupted in cancerous cells. Disruption of the pRb pathway liberates 
E2Fs and allows numerous genes to activate the progression of cells from G1 into S phase.  
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2.2.3 Evading Apoptosis 
Programmed cell death, or apoptosis, is present in latent form in all cell types throughout 
the body. This program triggers a series of steps under the influence of physiological signals. 
Apoptosis involves two components- sensors and effectors. The sensors are responsible for 
monitoring the extracellular and intracellular conditions of normality or abnormality that 
influence the survival or destruction of the cell. The intracellular sensors monitor abnormalities 
such as DNA damage, signaling imbalance provoked by oncogene action, survival factor 
insufficiency, or hypoxia. The survival signal is conveyed by IGF-1/IGF-2 through their 
receptors, IGF-1R, and by IL-3 and its cognate receptor (IL-3R). Death signals are conveyed by 
FAS ligand binding the Fas receptor and by TNFα binding TNF-R1. The effectors of apoptosis 
include intracellular proteases called caspases. Two important caspases, caspase -8 and -9, are 
activated by death receptors such as the FAS receptor or by the cytochrome C released from 
mitochondria, respectively. Cancer cells evade apoptosis by over expressing oncogenes such as 
Bcl-2 and c-Myc and through loss of proapoptotic regulating via mutations involving the p53 
tumor suppressor gene.  
2.2.4 Limitless Replicative Potential 
Most mammalian cells can only reproduce a limited number of times in laboratory 
cultures before they lose the ability to divide and become what is called senescent. The 
senescence can be circumvented by disabling pRb and p53 tumor suppressor proteins, allowing 
them to continue multiplying for additional generations until they enter into a second state, 
termed crisis. The crisis state is characterized by massive cell death associated with end-to-end 
fusion of chromosomes which acquires ability to multiply without limit, termed immortalization. 
Most tumor cells exhibit this immortalized state of unlimited replicative potential. Also, tumor 
cells maintain telomeres at a length above a critical threshold, which in turn, permits unlimited 
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multiplication of descendant cells.  
2.2.5 Induction of Angiogenesis 
 Angiogenesis is the growth of new blood vessels towards and within the tumor. Cancer 
cells trigger the production of growth factors to initiate angiogenesis, which is required for the 
tumor to grow. The newly formed blood vessels around the tumor provide a constant supply of 
oxygen and nutrients. The angiogenic signaling factors such as vascular endothelial growth 
factor (VEGF) and acidic fibroblast growth factors (FGF1/2) bind to transmembrane tyrosine 
kinase receptors expressed on endothelial cells.  The role of angiogenesis in cancer is elaborated 
in the following section of this chapter. 
2.2.6  Invasion and Metastasis  
 Tumor cells utilize the newly formed blood vessels and lymph circulation to migrate to 
distant tissues and organs. This stage is often associated with malignancy. The activation of 
extracellular proteases and the altered binding specificities of cadherins, cell adhesion molecules 
(CAMs), and integrins, are clearly central to the acquisition of invasiveness and metastatic 
ability. While malignant cells metastasize, they also express immunosuppressive compounds in 
order to evade the immune system. 
 Various direct and indirect therapies have been developed to inhibit the different events 
during carcinogenesis. Some of the well-known strategies include containing the cancer cells 
either by reverting them to normalcy or inducing programmed cell death. Other methods involve 
inhibition of angiogenesis, the process with which the tumor is deprived of oxygen and nutrients 
eventually forcing it to die, or controlling the metastasis and making the cancer cells sensitive to 
the immune system (Grothey, 2005). 
2.3 Overview of Angiogenesis 
Angiogenesis is a complex process in which existing mature blood vessels generate 
 7
sprouts, and these sprouts develop into complete new vessels. During angiogenesis, vascular 
cells proliferate at abnormally rapid rates of about 7-10 days, whereas normal process involves 
capillary cell division once every 7 years (Boik, 2001). 
Angiogenesis in tumor development involves at least four steps: (i) cancer cells or adjacent 
tissues secrete angiogenic factors, (ii) the basement membrane, which is a layer of specialized 
connective tissue and which also provides structural support to the capillary, serves as the 
connection point between the extracellular matrix (ECM), the ground substance surrounding 
cells and tissues, holding them in place, and the capillary itself.  This basement membrane 
dissolves and a bud begins to grow, (iii) vascular endothelial cells proliferate and migrate from 
the bud toward the angiogenic stimulus, and (iv) the sprout eventually forms a hollow tube called 
the lumen and joins its end with another sprout to form a new capillary vessel (Boik, 2001). 
2.4  Physiological and Pathological Angiogenesis 
2.4.1  Physiological Angiogenesis 
Physiological angiogenesis is tightly regulated by a network of stimulators and inhibitors 
and is short in duration. It plays an important role in reproduction, development of a child in 
mother’s womb, for connective tissue matrix formation, maintenance of vascular integrity during 
wound healing, repair process of damaged tissue, bone growth and bone fracture repair, and 
maintenance of oxygen delivery to working muscle under increased metabolic activity (Losso 
and Bansode, 2004).   
The mechanism of physiological angiogenesis involves several steps, which include (i) 
the removal of pericyte from endothelium and angiopoietin-2 (Ang-2)-catalyzed transformation 
of endothelial cells from a stable to a proliferative phenotype; (ii) growth factors, specially 
VEGF and VE cadherin catalyzed vessel hyper-permeability and matrix remodeling by the action 
of serine and matrix metalloproteinase; (iii) VEGF, FGF, and EGF catalyzed endothelial cell 
 8
proliferation; (iv) endothelial cell migration catalyzed by αvβ3 integrin, VEGF, and FGF; (v) VE 
cadherin and ephrin B2/ephrin B4catalyzed cell-cell contact; (vi) FGF, PDGF, TNF-α, and Eph-
2A catalyzed tube formation as blood conduits;  (vii) PDGF- and Ang1/Tie2-catalyzed 
proliferation and migration of mesenchymal cells along the new vessels and TGF-β catalyzed 
pericyte differentiation into mature pericytes; and finally (viii) Ang1/Tie2, PDGF, VE cadherins 
and TGF-β catalyzed vessel stabilization (Losso and Bansode, 2004). 
2.4.2  Pathological Angiogenesis 
 In a healthy body, the vasculature is quiescent, and in most healthy adult tissues, growth 
is almost non-existent (Hobson and Denekamp, 1984). Physiological angiogenesis occurs during 
embryo development where the vasculature is needed and is tightly regulated by a balance 
between stimulators and inhibitors. In adulthood, physiological angiogenesis occurs during 
wound healing and during the ovarian cycle. Pathological angiogenesis are mainly of two types: 
excessive and insufficient angiogenesis. Excessive angiogenesis occurs when angiogenic 
stimulators outbalance inhibitors and insufficient angiogenesis occurs when stimulators are 
deficient (Losso, 2002). 
 The mechanism of excessive angiogenesis involves: (i) retraction of pericytes from the 
abluminal surface of the capillary, (ii) release of proteases from the activated endothelial cells, 
(iii) protease-catalyzed dissolution of the basement membrane surrounding the pre-existing 
vessels, (iv) endothelial cell migration toward an angiogenic stimulus and their proliferation, (v) 
formation of tube-like structures, (vi) fusion of the formed vessels, and (vii) initiation of blood 
flow. Insufficient angiogenesis is characterized by (i) insufficient vascularization, (ii) delayed 
formation of granulation tissue, (iii) decreased collagen content, (iv) low breaking strength 
compared to normal tissue, loss of vascular tone, (v) higher content of oxidized lipids, (vi) 
absence of microtibular structures, (vii) impaired collateral vessel formation, and (viii) impaired 
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signal transduction pathways (Losso and Bansode, 2004). A list of human diseases associated 
with pathological angiogenesis is presented in Table 2.1. 
 Angiogenesis plays a critical role in the development of cancer. Solid tumors smaller than 
1 to 2 cm3 are not vascularized. They require oxygen and nutrients supplied by the blood vessels, 
which also remove the metabolic wastes from the tissues. Also, blood vessels serve as a medium 
for migration of cancerous cells to a different location in the body called metastasis. Cancer cells 
are capable of expressing several angiogenic factors including basic-fibroblast growth factor 
(bFGF), vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), transforming growth 
factor-β (TGF-β), and others that cause endothelial cell recruitment and proliferation. These 
stimuli, when expressed by the cancer cells, trigger the differentiation of the tumor endothelium 
into a mature vessel. However, the vascularization is rarely complete and tumor vessels show 
abnormal morphology (Tosetti et al., 2002).  
Additionally, oxygen and nutrients have difficulty diffusing to the cells in the center of 
the tumor beyond critical volume of 2 cm3. Depletion of oxygen availability induces hypoxia in 
tissues and enhances tumoral angiogenesis. Therefore, neovascularization is important for tumor 
survival and progression. It favors the transition from hyperplasia to neoplasia i.e. the passage 
from a state of cellular multiplication to a state of uncontrolled proliferation, which is 
characteristic of tumor cells. Neovascularization also influences the dissemination of cancer cells 
throughout the entire body eventually leading to metastasis formation. The vascularization level 
of a solid tumor is thought to be an excellent indicator of its metastatic potential.  
Some of the mechanisms to prevent the progression of angiogenesis in a tumor are: 
suppressing endogenous angiogenic factors, such as bFGF (basic Fibroblast Growth Factor) and 
VEGF (vascular endothelial growth factor), inhibiting enzymes (matrix metalloproteinases) 
responsible for the degradation of the basement membrane of blood vessels, inhibiting 
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endothelial cell proliferation; endothelial cell migration; and activation and differentiation of 
endothelial cells. The process regulating the molecular mechanism of switching angiogenesis 'on' 
or 'off' depends on the external and internal microenvironment, which includes metabolic stress, 
mechanical stress, immune/inflammatory response,, and genetic mutations (Losso and Bansode, 
2004).  
Table 2.1 A Partial List of Human Diseases Associated with Pathological Angiogenesis 
Pathological Angiogenesis 
Insufficient Excessive 
• Delayed wound healing  
• Ischemia (myocardial, peripheral, 
cerebral) 
• Stroke 
• Heart disease 
• Scleroderma 
• Infertility 
• Diabetic neuropathy 
• Systemic sclerosis 
• Coronary heart disease 
• Placental insufficiency 
• Impaired healing of fracture 
• Pulmonary and systemic hypertension 
• Vascular dementia 
• Lymphoedema 
• Impaired collateral vessel formation 
• Chronic non-healing ulcer 
 
• Rheumatoid arthritis 
• Multiple sclerosis 
• Age-related macular degeneration 
• Diabetes retinopathy 
• AIDS complications 
• Tumor growth and metastasis 
• Osteoporosis 
• Alzheimer’s 
• Parkinson’s 
• Obesity 
• Psoriasis 
• Hepatitis 
• Thyroid enlargement 
• Ocular neovascularization 
• Retinopathy of prematurity 
• Synovitis 
• Bone/cartilage destruction 
• Hematological malignancies 
(adapted from Losso and Bansode, 2004) 
Tumor vessels develop by sprouting from pre-existing vessels. Circulating endothelial 
precursors, shed from the vessel wall or mobilized from the bone marrow, can also contribute to 
tumor angiogenesis. Tumor cells can also grow around an existing vessel to form a perivascular 
cuff. Vascular endothelial growth factor (VEGF) and the  angiopoietin (Ang) family have 
predominant roles in vasculogenesis. The angiogenic activity of VEGF is tightly regulated by 
gene dosage. Several molecules, including a number of angiogenesis inhibitors, seem to be 
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involved mainly in tumor angiogenesis. The temporal and spatial expression of these regulators 
is not as well coordinated in tumors as it is in physiological angiogenesis and their mechanism of 
action is poorly understood. In addition, tumor vessels lack protective mechanisms that normal 
vessels acquire during growth. Tumor vessels lack functional perivascular cells, which are 
needed to protect vessels against changes in oxygen or hormonal balance, provide them 
necessary vasoactive control to accommodate metabolic needs and induce vascular quiescence. 
Finally, the vessel wall is not always formed by a homogenous layer of endothelial cells. Instead, 
it may be lined with only cancer cells or a mosaic of cancer and endothelial cells. Tumor blood 
flow is chaotic and variable, and leads to hypoxic and acidic regions in the tumors. Hypoxia may 
select for clonal expansion of cells that have lost their apoptotic response to hypoxia (Carmeliet 
and Jain, 2000).  
Tissues require a constant supply of oxygen in order to survive; beyond a certain size, 
simple diffusion of oxygen to metabolizing tissues becomes inadequate, and specialized systems 
of increasing complexity have evolved to meet the demands of oxygen delivery in higher animals 
(Pugh and Ratcliffe, 2003). The physiological response to hypoxia is aimed at maximizing 
oxygen intake and delivery to vital organs, increasing ventilation, heart rate, cardiac output, 
blood pressure, growth of capillary beds to supply vital organs, production of red blood cells, 
hemoglobin levels, and blood volume. Hypoxia can result in sympathoadrenal stimulation and 
lead to an increase in peripheral resistance. Postnatal hypoxia induces increased respiratory effort 
and causes a rise in cardiac performance (Huang et al., 2004).   
An acute hypoxic exposure will activate both the fast and delayed responses. The fast 
response involves, (a) metabolic changes, with a possible switch from mitochondrial based 
metabolism, fuelled by glycolysis and (b) activation of various plasma membrane ionic 
conductance, regulated either directly or indirectly by oxygen. The main difference between the 
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oxygen-sensing cells and other cell types in an organism, with respect to acute responses, is in 
the type of ion channels. Ion channels can be activated by specialized sensor cells in response to 
the hypoxic exposure and thus initiate specific signaling cascades that are able to integrate the 
signal generated at the sensor into a larger tissue or whole body response. The delayed responses 
are mainly based on genomic activation triggered by the up-regulation of a number of 
transcription factors (Pugh and Ratcliffe, 2003).  
A major advance in the understanding of the oxygen-sensing processes and of the 
mechanisms that regulates the cellular and tissue response to hypoxia came with the discovery of 
the hypoxia-inducible-factor (HIF-1). HIF-1 is ubiquitously expressed and participates in most 
chronic cellular responses to hypoxia. HIF-1 is a heterodimer composed of two subunits: HIF-1α 
and HIIF-1β. HIIF-1β, a factor that can dimerize with aryl hydrocarbon receptor (AHR) and 
activates the genes encoding cytochrome P450 enzymes involved in the metabolism of aryl 
hydrocarbons. Both subunits contain PAS (PER-ARNST-SIM) domains that mediate the 
heterodimer formation between the subunits and are also necessary for DNA binding. The main 
feature of HIF activity is that in normal (normoxic) conditions, both subunits are expressed, but 
only HIF-1β can be detected, because the HIF-1α subunit is rapidly degraded (Toescu, 2004). 
A large number of genes involved in angiogenesis are independently responsive to 
hypoxia in tissue culture such as nitric acid synthase involved in vascular tone, growth factors 
such as VEGF, angiopoietins, fibroblast growth factors and their various receptors, genes 
involved in matrix metabolism (matrix metalloproteinases, plasminogen activator receptors and 
inhibitors), and collagen prolyl hydroxylase. Also, many of the individual phenotypic processes 
during angiogenesis such as cell migration or endothelial tube formation can be induced by 
hypoxic tissue culture (Pugh and Ratcliffe, 2003).  
HIF plays an important role in tumor angiogenesis as many common cancers exhibit up-
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regulation of the HIF system influenced by multiple genetic and environmental mechanisms. 
Activation of hypoxia by the HIF system is also induced or amplified by a wide range of growth-
promoting stimuli and oncogenic pathways such as insulin, insulin-like growth factor-1, 
epidermal growth factor and mutant Ras and Src kinase pathways. Activation of HIF in cancer 
microenvironments occurs at the simplest level by physiological activation of the oxygen-
sensitive pathways by hypoxia within a growing mass of cells. The prolyl hydroxylation of HIF 
is often incomplete in tumor cells, even in fully oxygenated tissue culture. Iron imbalance 
associated with rapidly growing tumor cells is due to the enhanced activity of HIF hydroxylase, 
which degrades HIF-1α. This implies that the reduction in cellular iron availability, as well as 
hypoxia, limit HIF hydroxylase activity in cancer cells and contributes to activation of HIF in 
tumors. The interconnection between angiogenic and hypoxia pathway suggests a prevalent 
condition in cancer (Figure 2.1). Cell proliferation, HIF activation, and angiogenesis are all 
linked by pathways that operate physiologically to preserve oxygen homeostasis (Pugh and 
Ratcliffe, 2003).  
2.5 Inhibition of Angiogenesis 
2.5.1 Biomedical Approach- Success and Failure 
The anti-angiogenic drugs presently under investigation are being targeted either by 
specific biomarkers of angiogenesis (VEGF, bFGF, and IGF) or others that indirectly affect the 
endothelial cell function/response (matrix metalloproteinase breakdown). Some drugs such as 
thalidomide target both mechanisms simultaneously. Clinical trials are presently ongoing on 
direct administration of endogenous angiogenic inhibitors such as angiostatin, endostatin, and the 
gene transfer of DNA that encodes for angiogenesis inhibitors, including angiostatin and platelet 
factor IV. Synthetic angiogenic inhibitors that prevent endothelial cell division, such as synthetic 
derivatives of fumagillin are also underway (Rosen, 2000).  
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Figure 2.1 Multiple Interfaces of Hypoxia Pathways with the Angiogenic Growth Factor VEGF.  
(Pugh and Ratcliffe, 20031). 
Other strategies include counterbalancing the effects of ECM degradative enzymes 
(collagenase and gelatinase) with inhibitors such as TIMPs. The advantage of containing 
angiogenesis against tumor progression, unlike chemotherapy, is that anti-angiogenic inhibitors 
do not exhibit toxicity while drugs that target cell proliferation produce gastrointestinal 
symptoms and myelosuppression (Rosen, 2000). Drug resistance is another major problem with 
                                                 
1 Reproduced with permission from Nature Medicine (Pugh and Ratcliffe, 2003) copyright 
(2005) Macmillan Magazines Ltd. 
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chemotherapy as cancer cells are genetically unstable and prone to mutations. Alternately, 
angiogenic compounds mainly target endothelial cells and are cytostatic rather than cytotoxic 
(Rosen, 2000). 
2.5.2 Prevention of Cancer by Dietary Bioactive Compounds 
Increasing consumer knowledge of the link between diet and health has raised the 
awareness and demand for functional food ingredients and nutraceuticals (FitzGerald et al., 
2004). A major initiative in food product development is in discovering functional ingredients, or 
components possessing nutritional benefits, beyond the provision of essential nutrients and 
calories. Various dietary biomolecules have been associated anecdotally with functional and 
nutritional benefits and work is currently underway to characterize the mechanisms underlying 
these modes of action (Ward and German, 2004).  
 Sulforaphane, phenolic acids, and selenium from broccoli have been demonstrated to 
reduce the risk of cancer (Finley et al., 2005). Epidemiological studies focusing on tomato 
consumption and recent animal studies investigating lycopene and other phytochemicals in 
tomatoes, established its role against prostate cancer and cardiovascular diseases (Canene-Adams 
et al., 2005).  
 Herbal flavonoids (quercetin, curcumin, rutin, and silymarin) and one whole herb mixture 
(ginseng powder) have been shown to suppress aberrant crypt foci (ACF) in an azoxymethane 
(AOM)-induced rat colon cancer model. The ability of quercetin and curcumin to modulate 
ACFs correlates well with their ability to induce apoptosis by affecting caspase 9, Bax 
(proapoptotic) and Bcl-2 (antiapoptotic) proteins from the colon cells via the mitochondrial 
pathway (Volate et al., 2005). Phytochemicals, including phenolics and flavonoids from apples, 
have been shown to inhibit mammary cancer growth in a rat model due to their antioxidant and 
antiproliferative activities (Liu et al., 2005). Preclinical and clinical evidence indicate that 
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indole-3-carbinol (I3C), a key bioactive food component in cruciferous vegetables, has multiple 
anticarcinogenic and antitumorigenic properties. Evidence that p21, p27, cyclin-dependent 
kinases, retinoblastoma, Bax/Bcl-2, cytochrome P-450 1A1, and GADD153 are all targets for 
I3C already exists. Modification of nuclear transcription factors, including Sp1, estrogen 
receptor, nuclear factor kappaB, and aryl hydrocarbon receptor, may represent a common site of 
action to help explain downstream cellular responses to dietary I3C, and ultimately to its 
anticancer properties (Kim and Milner, 2005).  
2.5.3 Dietary Bioactive Compounds as Anti-angiogenic Compounds against Cancer 
The rate-limiting factor in angiogenesis seems to be increased vascular permeability and 
vascular endothelial growth factor (VEGF), one of the most potent inducers of permeability 
known to play a key role in angiogenesis. Reduction of VEGF production and reduced vascular 
permeability has been suggested as measures of pathological angiogenesis prevention (Boik, 
2001). VEGF is produced in response to hypoxia (low oxygen) conditions, which are prevalent 
within most tumors (Hanahan and Weinberg, 2000; Kieran et al., 2003). Other growth factors, 
such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), tumor necrosis 
factor (TNF), and transforming growth factor-beta (TGF-β), which are present in macrophages, 
also produce VEGF. The expression of VEGF can be reduced by antioxidants, PTK inhibitors, 
PKC inhibitors, and leukotriene inhibitors, as well as inhibitors of AP-1 (Tsai et al., 2003; Fierro 
et al., 2002; Matsushita et al., 2000).  Reduced production of VEGF has been reported with 
genistein, a PTK inhibitor, EPA, a PKC inhibitor, and curcumin, an AP-1 inhibitor.  Epigallo 
catechin gallate (EGCG), curcumin, caffeic acid phenethyl ester (CAPE), and genistein have also 
been reported to reduce EGF and PDGF signaling in a variety of cells (Sah et al., 2004; Smith et 
al., 2004; Zheng et al., 1995; Dean et al., 1989). Other flavanoids, such as luteolin and apigenin, 
can inhibit in-vitro angiogenesis by inhibition of VEGF expression during hypoxia by 
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suppression of HIF-1α and p53 tumor suppressor gene (Hasebe et al., 2003; Fang et al., 2005). 
The primary effect of VEGF is to minimize the vascular permeability, which is caused by pro-
inflammatory cytokine activity of VEGF, especially VEGF-A. VEGF-A regulates enzymes such 
as cyclooxygenase-2 (COX-2), adhesion molecules (e.g. E-selectin, VCAM-1), and pro-
coagulant factors (e.g. tissue factor) (Wilkinson-Berka, 2004). Some of the naturally derived 
compounds that are believed to reduce vascular permeability are: anthocyanidins, Butcher’s 
broom, Centella asiatica, horsechestnut, and proanthocyanidins (Boik, 2001). 
2.5.4 Role of Sphingolipids in Angiogenesis 
The role of sphingolipids in angiogenesis is not well established. However, recent studies 
show that sphingolipids could mediate cell migration and angiogenesis by their well-known 
mechanism as secondary messenger (Le Stunff et al., 2004; Wang et al., 2003). Sphingosine-1-
phosphate (S1P), formed by sphingosine kinase, has been proven to complex with the EDG-1 (a 
GPCR) and mediates cell migration and vascular maturation (Rosenfeldt et al., 2001; Morales-
Ruiz et al., 2001). EDG-1 functions as an integrator linking the PDGFR to lamellipodia 
extensions and cell migration.  S1P stimulated EDG-1, results in activation and integration of 
downstream signals important for directional movement toward chemoattractants, such as PDGF.  
PDGF, which further stimulates sphingosine kinase and leads to increased S1P levels in many 
cell types, also induces translocation of sphingosine kinase to membrane ruffles (Katsuma et al., 
2000). The study conducted by Ryu et al., (2002) established that S1P could stimulate smooth 
muscle cells (SMCs) and endothelial cells, modulate vascular tone bimodally by directly 
constricting SMCs and stimulating production of nitric oxide, and stimulate endothelial 
permeability and angiogenesis. On the other hand, ceramide induced apoptotic cell death while 
S1P acted as a survival factor. S1P counteracts the pro-apoptotic effects of ceramide through 
protein kinase C and inhibits apoptosis in macrophages by depressing acidic-Sphingomyelinase 
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(aSmase) (Yabu et al., 2005).  
A recent study conducted by Yabu et al., (2005) on zebrafish demonstrated that S1P 
decreases ceramide content by inhibiting neutral Sphingomyelinase (nSMase) and restores a 
thalidomide-induced vascular defect in zebrafish embryo by increasing the expression of 
neuropilin-1 and Flk-1, suggesting that the balance between ceramide and S1P-mediated signal 
regulates angiogenesis through VEGF receptors, Flk-1, and neuropilin-1. 
2.6 In Vitro and In Vivo Angiogenesis Assay 
Angiogenesis assays are used to test efficacy of both pro- and anti-angiogenic agents, 
which rely on both in vitro and in vivo tests. The selection of assays depends on the criteria under 
investigation and generally involves a combination of assays in providing the necessary 
information. In vitro assays are generally used for quantification purpose while in vivo assays are 
used to substantiate the in vitro results. Also, in vivo assays are essential because of the complex 
nature of vascular response to test reagent (Staton et al., 2004). The ideal assay would be 
reliable, straightforward, easily quantifiable and physiologically relevant. It is usually 
recommended a combination of the cellular and molecular events in angiogenesis be used to 
examine the full range of effects for a given test compound (Auerbach et al., 2003). This section 
elaborates on the most commonly used in vitro and in vivo assays for accessing the efficacy of 
compounds towards angiogenesis. 
2.6.1 In Vitro Assays 
2.6.1.1 Cell Proliferation 
There are two major classes of proliferation assays: those that determine net cell number 
and those that evaluate cell-cycle kinetics. Net cell number can be established by use of a 
haemocytometer or by use of an electronic counter such as a Coulter counter. Other techniques 
involve staining, such as 3-(4,5-demethylthiazol-2-yl)-2,5-diphenylltetrazolium bromide) (MTT), 
 19
a tertrazolium salt that gives blue formazan product when cleaved by active mitochondria, and 
assessing DNA synthesis using DNA binding dye (thymidine) to measure the cell viability with 
colorimetric techniques. An alternative method for assessing proliferation is by cell-cycle 
analysis, using DNA binding molecules (bromodeoxyuridine, BrdU) coupled with flow 
cytometry analysis (Auerbach et al., 2003).  
2.6.1.2 Cell Migration 
Blind-well chemotaxis (modified Boyden chamber) is the most commonly used assay for 
measuring the migration of cells in response to a test factor. The cells are placed on the upper 
layer of a cell permeable filter placed in the medium below the filter. This requires cell 
enumeration to measure the number of cells that migrate across the filter compared with that 
which was retained in the upper layer. This process reflects the conditions that are operative in 
vivo and lends itself to testing concentration gradients of the compound under study (Staton et 
al., 2004).  
2.6.1.3 Tube Formation 
One of the most specific tests for angiogenesis is the measurement of the ability of 
endothelial cells to form three-dimensional structures (tube formation).  Endothelial cells 
spontaneously form tubules in vitro by laying down approximate extracellular matrix 
components. Endothelial cells are usually cultured on matrices consisting of fibrin, collagen and 
Matrigel, which stimulates the attachment, migration and differentiation of these cells into 
tubules in a manner comparable to in vivo conditions (Staton et al., 2004).  
2.6.2 In Vivo Assays  
There are currently three commonly used in vivo approaches for assaying compounds 
with regards to vessels growth: (1) microcirculatory preparations in animals, (2) vascularization 
into biocompatible matrix implants, and (3) excision of vascularized tissues. Although the first 
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method is an in vivo technique, the latter two are in vitro assays that require subsequent in vivo 
validation. In vivo assays are usually expensive, are experimentally exhaustive and are 
accountable for the study of angiogenesis but not for drug screening. Therefore, there is an 
important requirement for an inexpensive and faster in vivo technique for screening angiogenesis 
(West et al., 2001).  
2.6.2.1 Chorioallantoic Membrane (CAM) Assay as an Angiogenesis Model System 
The study of the angiogenic process and the search for novel therapeutic agents to inhibit 
or stimulate angiogenesis has employed a wide range of in vivo ‘angiogenic’ assays. These differ 
greatly in their difficulty, quantitative nature, rapidity, and cost. The classical in vivo models 
include the rabbit ear chamber, hamster cheek pouch, dorsal skin chamber, dorsal skin and air-
sac model, anterior chamber/iris and avascular corneal pocket assay, and the chick embryo 
chorioallantoic membrane (CAM) assay. Most recent methods involve implantation of preloaded 
matrigel or alginate plugs, or collagen or polyvinyl sponges, and zebrafish screening. CAM is the 
most widely used in vivo model largely due to its simplicity and low cost (Ribatti et al., 2000). 
Folkman and coworkers initially developed the CAM assay to examine the angiogenic 
activity of tumor tissues. There are two different methods commonly employed. The most widely 
used method is performed with CAM assay in situ, the samples (up to two per egg) are applied 
through a window made in the shell. The other technique involves transfer of the early, 3- or 4-
days-old, embryo and its extra-embryonic membranes to a glass Petridish for further 
development. This gives a wider surface area, allowing multiple sample applications on the same 
egg, and provides easier viewing and photography, but suffers from poor embryo viability 
(Ribatti et al., 2000).  
However, CAM has several limitations for large scale screening: (1) the CAM assay 
takes a minimum of 10 days, compared with 1-3 days for the zebrafish assay (2) the number of 
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compounds and/or dilutions that can be tested at one time is limited by availability and cost of 
egg production compared with inexpensive zebrafish assay embryo production, and (3) the assay 
is more difficult to quantitate than the zebrafish assay, which impedes the generation of dose-
response relationships (Serbedzija et al., 1999). 
2.6.2.2 Zebrafish Assay as Angiogenesis Model System 
The zebrafish (Danio rerio) is a small tropical fish, which develops ex utero and is 
optically transparent during early development. Between 1 to 6 days post-fertilization (dpf), 
zebrafish develop discrete organs and tissues, including brain, heart, liver, pancreas, kidney, 
intestines, bones, muscles, nervous systems, and sensory organs. These organs and tissues have 
been demonstrated to be similar to their mammalian counterparts at the anatomical, 
physiological, and molecular levels. Historically, zebrafish have provided a powerful model for 
studying the genetics and developmental biology of vertebrates, as well as for assessing the 
aquatic toxicity of environmental pollutants, but in more recent years the value of the zebrafish 
has been increasingly recognized as a model organism for drug screening, target validation, and 
toxicological studies (Parng, 2005).  
Zebrafish have 50 chromosomes that contain orthologs or homologs of most human 
genes. The conservation in the proteins’ functional domains, including substrate binding regions, 
ligand binding regions, enzyme catalytic domains, DNA binding motifs, and nucleus 
translocation signal sequences is considerably higher between zebrafish and humans. Since these 
domains are highly conserved or even structurally identical in zebrafish and humans, drugs 
designed to interact with these functional domains in a protein of interest elicit comparable 
pharmacological effects (Parng, 2005). 
The major advantages of a zebrafish-based assay compared with existing assays are: (1) 
hundreds of compounds can be tested simultaneously using a microplate format, (2) the assay is 
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fast, approximately 1-3 days from addition of compounds to assay results, (3) embryo 
maintenance is easy during assay procedures, and (4) compound addition and embryo assessment 
is straight-forward due to ease of access (Serbedzija et al., 1999). 
Zebrafish have several inherent advantages for drug screening as they are small, 
inexpensive to maintain, and easily bred in large numbers (a single spawning produces 100 to 
200 eggs). Development during the segmentation period is shown in Figure 2.2. Adult zebrafish 
are 3-cm-long. The larvae, which are only 1-to 4-mm-long, can live for 7 days in single well of 
standard 96 or 386-well plates supported by nutrients stored in their yolk sacs. Administration of 
drugs to zebrafish is straight forward; zebrafish larvae can absorb small molecules diluted in the 
surrounding water through their skin. Since zebrafish begin to swallow at 72 h post-fertilization 
(hpf), drugs can be delivered via the oral route for assays performed after this time. Highly 
hydrophobic compounds can be injected into the yolk sac, the sinus venous, or the veins. 
Compared to testing in other animal models, statistically significant numbers of zebrafish can be 
used for each assay and only a small amount (milligram scale) of drug is required. In addition, 
the transparency of the embryo provides easy accessibility for in vivo observations in live or 
whole mount-fixed specimens, including visualization of vital dyes, fluorescent tracers, 
antibodies, and riboprobes. Therefore, the zebrafish enables highly efficient phenotypical 
analysis and rapid assay for primary drug screening (Parng, 2005). 
2.6.2.3 Angiogenesis in Zebrafish 
The study of zebrafish, a leading model organism for developmental biology is rapidly 
expanding to include human disease and mechanisms that have been developed in several 
therapeutic areas, including blood diseases, diabetes, muscular dystrophy, neurodegenerative 
disease, angiogenesis and lipid metabolism. Recent literature suggests that the zebrafish has 
served as a novel in vivo model for drug discovery through the identification of novel drug 
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targets, validation of these targets, and screening for new therapeutic compounds (Serbedzija et 
al., 1999). Target identification refers to the process of identifying gene products that, when 
modulated by a drug, can have a positive impact on disease state progression (Rubinstein, 2003). 
Vasculature patterning in zebrafish embryo has been recently studied and used for drug 
screening to determine the anti-angiogenic properties of these compounds. The embryo vessels 
in the vertebrate trunk are a single large artery and vein, generated by the differentiation and 
coalescence of angioblasts from the lateral mesoderm, which is called vasculogenesis.  
The sprouting of new blood vessels from the pre-existing vessels is termed angiogenesis. 
Angiogenesis at a cellular level involves localized endothelial cell proliferation and migration, 
followed by remodeling of the nascent vessel, the latter including the removal, growth or 
subdivision of the new channels. As discussed earlier several growth factors have been shown to 
be crucial for normal angiogenesis in the embryo. Vascular endothelial growth factor, VEGF, is 
expressed in the vicinity of sprouting vessels, its receptor (VEGF-R2/Flk-1/kdr) is located on the 
angioblast and new vessels are required for vasculogenesis and angiogenesis. Angiopoietin 1 and 
angiopoietin 2, and their receptor Tie 2, are reciprocally expressed in surrounding mesenchyme 
and early vessels. They appear to function in vascular remodeling and stabilization. Several 
EphB receptors and ephirnB ligands are expressed, some with arterial versus venous specificity, 
both on vessels and in surrounding tissues, and are required for remodeling of angiogenesis. 
In zebrafish, cells in the lateral posterior mesoderm express endothelial and 
hematopoietic markers, suggesting that they include bipotential precursors for both the 
hematopoietic and angioblastic lineages, termed hemangioblasts (Crosier et al., 2002). Childs et 
al., 2002 determined that the angiogenic precursor cells arise in the lateral posterior mesoderm, 
at an axial level that corresponds to the eventual sprout, and migrate medially to the aorta. 
There they then sprout dorsally to connect to aorta with dorsal longitudinal anastomotic vessel 
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Figure 2.2 Development of Zebrafish Embryo during the Segmentation Period.  
Left side views, except where noted, with anterior up and dorsal to the left. A: 2-somite stage 
(10.7 h). Somite 2 is the only one entirely pinched off at this time, the arrow indicates its 
posterior boundary; somite 1 is just developing a clear anterior boundary at this stage. B: 2-
somite stage, dorsal view. The notochord rudiment shows between the arrows, just anterior to the 
level of somite 1. C: 2-somite stage, ventral view. The arrow indicates the polster. D: 4-somite 
stage (11.3 h). Somite 1 now has an anterior boundary. The optic primordium begins to show 
(arrow). E: 4-somite stage, dorsal view, focus is on the notochord at the level of the boundary 
between somites 2 and 3. Note at the top how the brain rudiment and underlying axial mesoderm 
prominently indent the yolk cell in the midline. F: 5-somite stage (11.7 h), ventral view, focus is 
on the newly forming Kupffer's vesicle (arrow). G: 8-somite stage (13 h). The optic primordium 
has a prominent horizontal crease (arrow). The midbrain rudiment lies just dorsal and posterior 
to optic primordium. The segmental plate, developing paraxial mesoderm posterior to the somite 
row, is clearly delineated. H: 13-somite stage (15.5 h). Somites begin to take on a chevron shape. 
The yolk cell begins to look like a kidney-bean, heralding formation of the yolk extension. The 
tail bud becomes more prominent and Kupffer's vesicle shows from the side (arrow). I: 14-
somite stage (16 h), dorsal view, and positioned so that the first somite pair is at the center. Note 
at the top the shape of the brain primordium, at the level of the midbrain. J: 15-somite stage (16.5 
h). The arrow shows Kupffer's vesicle. K: 15-somite stage from a dorsal-view to show the optic 
primordia. Kupffer's vesicle is also nearly in focus. L: 17-somite stage (17.5 h). The otic placode 
begins to hollow. The yolk extension is now clearly delimited from the yolk ball as the tail 
straightens out. M: 20-somite stage (19 h). The arrow indicates the otic vesicle. N: 25-somite 
stage (21.5 h). The telencephalon is prominent dorsally, at the anterior end of the neuraxis. O: 
25-somite stage, dorsal view. The hindbrain's fourth ventricle shows at the top. Scale bars: 250 
µm (Sprague et al. 20012). 
                                                 
2 Images for this dissertation were retrieved from the Zebrafish Information Network (ZFIN), the 
Zebrafish International Resource Center, University of Oregon, Eugene, OR 97403-5274; World 
Wide Web URL: http://zfin.org/; [September, 2005]. 
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 (DLAV). Three cell types constitute the sprout. Two resemble T-joints, one pointing dorsally off 
the aorta, and one pointing ventrally off the DLAV. The third constitutes a connecting tube in 
between as shown in Figure 4.2. 
Vasculogenesis in zebrafish involves the differentiation of hemangioblasts from 
mesoderm, with a subsequent differentiation of angioblasts and endothelial cells. By the 12 
somite stage (approximately 12 h post-fertilization, h pf), cells of the lateral mesoderm start 
expressing hemangioblast markers such as SCL/Tal-1 and Flk-1. These mesodermal bands 
converge until they lie within the embryo between the somites and the yolk sac, and form the 
intermediate cell mass (ICM). By 24 hpf, a simple circulatory loop consists of the dorsal aorta 
(DA) and axial vein (AV); blood cells subsequently differentiate from cells within the ICM. By 
72 hpf, a functioning vasculature has developed, including the major trunk vessels and 
angiogenic sprouts, such as the subintestinal vessels (SIVs). Vessels in the posterior tail further 
differentiate and express SCL/Tal-1 at 72 hpf (Serbedzija et al., 1999). 
2.7 Overview of Sphingolipids 
 Sphingolipids are a class of complex lipids containing an amide-linked fatty acid and a 
long-chain (sphingoid) base that are important structural components of cell membranes, and are 
well recognized in both vertebrate and invertebrate cells. Different combinations of sphingoid 
long-chain bases, fatty acids, and head group moieties lead to a large number of sphingolipids 
and sphingolipids as illustrated in Figure 2.4. They are also involved in cellular processes such as 
cell proliferation, growth, migration differentiation, senescence, and apoptosis. Recent studies 
have shown that sphingolipids play an important role in signaling and therefore cell fate (Testi, 
1996). Intercellular effects of a particular sphingolipid metabolite depend on cell type, the stage 
of cell development, and the ratio between different metabolites on the specific subcellular 
compartment of generation. Sphingolipids contribute to cellular signaling either by acting as first 
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Figure 2.3 Model of the Construction of a Zebrafish ISV.  
An intersegmental vessel (ISV) is composed of three types of endothelial cells, distinguished by 
their morphologies. The dorsal connection to the DLAV is a T-shaped cell (blue); the ventral 
connection to the aorta is an inverted ‘T’ (red). The connecting cell (green) courses between the 
somites ventral to the notochord-neural tube interface, and appears not to follow the somite 
boundary dorsally, where it runs directly to the DLAV. (Childs et al., 20023). 
                                                 
3 Reproduced with permission, Childs et al., 2002 and The Company of Biologists Ltd, 
Copyright (2005). 
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Figure 2.4 Structures of Sphingolipids. 
The pro-apoptotic action of ceramide can be mimicked by small molecules such as C2 and C6 ceramides, or by analogues that inhibit 
clearance of ceramide, such as B13 (shown in red), an inhibitor of acid CDase (Ogretmen and Hannun, 20044). 
                                                 
4 Reproduced with permission from Nature Reviews Cancer (Ogretmen and Hannun, 2004)copyright (2005) Macmillan Magazines 
Ltd. 
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messengers binding to a seven-spanning, G protein-coulped receptor subfamily, or as 
intracellular second messengers, capable of interacting with a multiplicity of targets 
(Colombaioni and Garcia-Gil, 2004). 
2.7.1 Synthesis of Sphingolipids  
 Metabolism of sphingolipids utilizes a diverse group of enzymes and de novo synthesis 
of sphingomyelin, sphingomyelinases, ceramidases, and sphingosine kinases (Figure 2.5). All are 
regulated by stimuli such as growth factors and stress, as well as some pathological conditions. 
De novo synthesis of sphingolipids (shown in Figure 2.6), occurs at the cytosolic face of the 
endoplasmic reticulum and is initiated by condensation of serine and palmitoyl-CoA via serine 
palmitoyl-transferase. The resulting keto-sphinganine is reduced to form sphinganine and N-
acylated by ceramide synthase to dihydroceramide, which then desaturates to yield ceramide (N-
acylsphingosine). Ceramide can be phosphorylated by ceramide kinase to ceramide-1-phosphate, 
or can serve as a substrate for the synthesis of sphingomyelin by addition of phosphocholine, or 
glycolipids by addition of oligosaccharides. Ceramide can also be metabolized by ceramidase to 
release sphingoid bases that can either be reutilized for complex sphingolipid biosynthesis or 
phosphorylated. Sphingosine is phosphorylated to yield sphingosine-1-phosphate, which is then 
dephosphorylated by lipid phosphate phosphatase or cleaved by the sphingosine-1-phosphate 
lyase (Colombaioni and Garcia-Gil, 2004).  
2.7.2 Sphingolipids as Extracellular Receptors 
Recent studies have identified sphingosine-1-phosphate (S1P) and lysophosphotidic acid 
(LPA) as extracellular ligands for a family of G protein-coupled receptors (GPCRs) (Radeff-
Huang et. al., 2004). This family of receptors is also known as endothelial differentiation gene 
(EDG)-regulated family. These receptors have a distinct coupling pattern to various G proteins 
and therefore are capable of activating multiple intracellular signaling pathways.  The binding of 
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Figure 2.5 De novo Synthesis and Metabolism of Sphingolipids.  
De-novo-generated ceramide in the endoplasmic reticulum (ER) is transported by CERT to the 
Golgi membranes (a) for the synthesis of sphingomyelin (SM). Ceramide can also be converted 
to glucosylceramide (GlcCer) by the action of glucosylceramide synthase (GCS) in the Golgi, 
but this is not CERT-dependent. In mitochondria (b), ceramide is generated by neutral 
sphingomyelinase (N-SMase), which can be activated by reactive oxygen species (ROS) 
generated in mitochondria. Ceramide generated here can activate the ceramide-activated protein 
phosphatases protein phosphatase 1 (PP1) and PP2A. PP2A can then dephosphorylate and 
inactivate anti-apoptotic proteins such as BCL2 and AKT, leading to apoptosis. PP1 also acts on 
the pro-apoptotic protein BID. In the ER/nucleus (c), de-novo-generated ceramide can activate 
PP1, which leads to dephosphorylation of SR proteins that mediate the alternative splicing of 
BCL-X. In lysosomes (d), ceramide is generated by the action of acid SMase (A-SMase). 
Ceramide can activate cathepsin D and mediate activation of the pro-apoptotic protein BID, 
cleaving it to truncated BID (tBID) leading to activation of caspase-9 and caspase-3, resulting in 
apoptosis. Ceramide generated in lysosomes can also be used as a substrate for acid ceramidase 
for the generation of sphingosine and, from this, the generation of sphingolipids in other 
compartments. The generation of ceramide in the plasma membrane (e) can occur within specific 
sub-compartments of the membrane known as lipid rafts. Ceramide produced here can affect 
specific signaling pathways generated by receptors aggregated in the rafts, such as FAS. CDase, 
ceramidase. SMS, sphingomyelin synthase (Ogretmen and Hannun, 20045).  
 
                                                 
5 Reproduced with permission from Nature Reviews Cancer (Ogretmen and Hannun, 2004) 
copyright (2005) Macmillan Magazines Ltd. 
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the extracellular receptors activates different signaling pathways involving trimeric G proteins, 
which in turn, control adenylate cyclase, phospholipases C and D (PLC, PLD), PI3K, ERK, JNK, 
p38, small GTPases such as Ras and Rho, and non-receptor activated protein-tyrosine kinases 
and tyrosine phosphatases (Servitja et al., 2003). The responses elicited by S1P and LPA include 
effects on cell proliferation, survival, morphology, adherence, chemotaxis, and activation of 
ionic conductance. 
2.7.3 Sphingolipids as Secondary Messengers  
Sphingolipids and their derived products, including ceramide, sphingosine, and 
sphinganine, are potent suppressors of growth (Yang et al., 2004). Sphingolipids can modify the 
activity of a number of proteins, including receptors, ion channels, and enzymes as well as 
intracellular calcium levels. The interaction of sphingolipids, especially SM and cholesterol, 
drives the formation of plasma membrane rafts (also known as glycosphingolipid-enriched 
microdomains [GEMs] or detergent-insoluble glycosphingolipid-enriched microdomains 
[DIGs]).These rafts, formed in the Golgi apparatus, are targeted to the plasma membrane. SM 
hydrolysis to ceramide, usually via acidic-Sphingomylinase (aSMase), occurs within the rafts. 
Ceramide generated within rafts appears to alter the raft structure. These microdomains rapidly 
fuse into larger domains, termed ‘platforms’ and form caps on the cell surface to facilitate 
oligomerization. FAS trimers localize to these domains to form higher order structure for the 
oligomerization of the downstream adaptors of FADD/MORT-1 and caspase-8, which activates 
the FAS apoptotic signal (Kolesnick, 2002). Sphingomyelin hydrolysis/ceramide accumulation 
involves extracellular/ biological inducers such as ionizing and ultraviolet radiation, Fas ligand, 
tumor necrosis factor, oxidative stress, 1, 25-dihydroxyvitamin D3, interferon gamma, endotoxin, 
chemotherapeutic agents, nerve growth factor, heat, CD28, IL-1, progesterone, retinoic acid, 
serum withdrawal, as well as human immunodeficiency virus (Lee and Amoscato, 2004). 
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Figure 2.6 Pathways of Sphingolipid Metabolism.    
Ceramide can be formed de novo (pink) or from hydrolysis of sphingomyelin (blue) or 
cerebrosides (green). Conversely, ceramide can be phosphorylated by ceramide kinase to yield 
ceramide-1-phosphate, or can serve as a substrate for the synthesis of sphingomyelin or 
glycolipids. Ceramide can be metabolized (orange) by ceramidases (CDases) to yield 
sphingosine, which in turn is phosphorylated by sphingosine kinases (SKs) to generate 
sphingosine-1-phosphate (S1P). S1P can be cleared by the action of specific phosphatases that 
regenerate sphingosine or by the action of a lyase that cleaves S1P into ethanolamine-1-
phosphate and a C16-fatty-aldehyde. C1PP, ceramide-1-phosphate phosphatase; CRS, 
cerebrosidase; CK, ceramide kinase; CS, ceramide synthase; DAG, diacylglycerol; DES, 
dihydroceramide desaturase; GCS, glucosylceramide synthase; PC, phosphatidylcholine; S1PP, 
S1P phosphatase; SMS, sphingomyelin synthase; SMase, sphingomyelinase; SPT, serine 
palmitoyl transferase(Ogretmen and Hannun, 20046).  
 
                                                 
6 Reproduced with permission from Nature Reviews Cancer (Ogretmen and Hannun, 2004) 
copyright (2005) Macmillan Magazines Ltd. 
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2.8 Role of Sphingolipids in Apoptosis, Cell Proliferation, and Differentiation 
2.8.1 Sphingosine 
Sphingosine-induced apoptosis requires the release of cytochrome C from mitochondria, 
the activation of caspase-3, and the inhibition of anti-apoptotic pathways such as that mediated 
by AKT kinase, a serine/threonine kinase that protects cells from apoptosis induced by a variety 
of extracellular stresses (Yang et al., 2004). Other possible mechanisms include relocation of 
lysosomal proteases to the cytosol leading to the release of cathepsin-D and one or more cysteine 
proteases resulting in caspase activation and a change in the mitochondria membrane potential. 
Sphingosine is also implicated in mitochondria-dependent, Fas-mediated apoptosis (Cuvillier et 
al., 2000). 
2.8.2 Ceramide 
Ceramide can signal apoptosis by a pathway involving a kinase suppressor of 
Ras/Ras/raf1/MEK1. Ceramide can bind to and regulate PKC ζ activity, which further interacts 
with Ras and activates MEK/ERK (Ruvolo, 2003; Willaime et al., 2001). Cathepsin-D, an 
endosomal acidic aspartate protease involved in apoptosis, can also be bound by ceramide 
(Heinrich et al., 2000). Similarly, ceramide activated protein phosphatases (PP1 and PP2A), its 
substrates and protein kinases are involved in apoptosis (Yang et al., 2004). 
An increase in ceramide levels has been observed in response to a number of cancer 
chemotherapeutic agents, including etoposide, vincristine, daunorubicin, fludarabine, paclitaxel, 
PSC 833, fenretinide, and irinotecan, or after radiation treatment (Reynolds et al., 2004).  
Strategies that elevate ceramide levels are being used for therapies aimed to arrest growth or 
promote apoptosis (Kolesnick, 2002). Contrary to its apoptotic activity, ceramide also forms 
products that stimulate cell growth and proliferation. For example, sialo-glucosphingolipid 
(gangliosides), a metabolite of ceramide, inhibits the immune system’s dendritic cells, which are 
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vital for the complete destruction of cancer cells (Radin, 2004). Therefore, ceramide metabolism 
plays a vital role in normal cell function and stability due to its interacting effect in growth/death 
or differentiation of normal cells. 
2.8.3 Sphingosine-1-Phosphate (S1P) 
S1P has been implicated as a second messenger that promotes cellular proliferation and 
survival by protection against ceramide-mediated cell death. The cell surface S1P receptors (also 
known as the EDG receptors) play an important role in intercellular signaling (Reynolds et al., 
2004).  The balance between ceramide and S1P as messengers may be an important factor 
determining survival or death of mammalian cells. Studies suggest that S1P antagonizes 
ceramide-mediated biologic responses, while ceramide activates various protein kinase C (PKC) 
isoforms, which may contribute to the S1P rheostat by activating the pro-life transcription factor 
NFkappa-β (Reynolds et al., 2004).  
2.9 Sphingolipids in Food 
2.9.1 Sphingolipid Content in Plant and Animal Sources 
 Sphingolipids in food are found in varying amount from plant and animal sources. The 
amount of sphingolipids in food commodities and its yearly consumption are listed in Table 2.2.  
The amounts vary considerably, from the low micromoles per kilogram in fruits and some 
vegetables to ~2 mmol/kg (1–2 g/kg) in dairy products, egg and soybeans. Except for milk 
(Jensen, 1995; Keenen and Patton, 1995), little is known about variation in sphingolipid amounts 
over season (day of lactation, in the case of milk), losses during food preparation, and other 
aspects of food chemistry.  
2.9.2 Sphingolipids from Milk as Dietary Bioactive Compounds 
 Milk has afforded compelling examples of a food material designed by selective pressure 
to provide optimal health to healthy mammalian offspring. Milk contains components that are 
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more than assembled essential amino acid and that provide biological activities that improve the 
competitive success of offspring who consume them (Ward and German et al., 2004).  
 Milk contains (per L) 39–119 mg of sphingomyelin, 6–11 mg of glucosylceramide, 6.5–15 
mg of lactosylceramide and ~11 mg of gangliosides (~9–13 mg GD3, 1.2 mg GD1b1, 0.7 mg GM2, 
0.3 mg GM3 and 0.001 mg GM1) (Jensen, 1995); the lipid backbones of milk sphingomyelin have 
mainly sphingosine (d18:1t4, with smaller amounts of sphinganine and other chain length 
homologs) and 16:0, 22:0, 23:0 and 24:0 as the major fatty acids (Vesper et al., 1999; Morrison, 
1969; Schmelz et al., 1996; Zeisel et al., 1986). 
Table 2.2 Sphingolipids in Food and Yearly Sphingolipid Consumption in US 
Food Source Sphingolipid 
content 
µmol/kg 
Food 
consumed 
per capita 
kg/y 
Sphingolipids 
consumed per 
capita 
µmol/y 
Dairy Products   38,464 
Meat products and 
fish 
  34,270 
Eggs 2250 14 31,500 
Cereals    
Wheat flour 576 66 38,016 
Total sphingolipids 
intake (µmol/y) 
  153,551 
Total sphingolipids 
intake (g, calculated 
as sphingomyelin) 
  116 
(adapted from Vesper et al., 1999) 
 
2.9.3  Structural Variation of Sphingolipids in Food 
 The sphingolipid backbones, fatty acids, and headgroups vary considerably with the type of 
food. Most foods of mammalian origin (beef, milk) or poultry (Chicken, Turkey, eggs) have a 
wide spectrum of complex sphingolipids (sphingomyelins, cerebrosides, globosides, gangliosides 
or sulfatides) that are comprised of many different headgroup components (phosphocholine, 
glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine, N-acetylneuraminic acid, 
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fucose and other carbohydrates) and ceramide backbones (d18:14, d18:0 and t18:0, with amide-
linked fatty acids of 16–30 carbon atoms in length, some of which have an hydroxyl group) 
(Merrill and Sweeley, 1996 ). In contrast, the complex sphingolipids of plants are mainly 
cerebrosides (mono- and oligohexosylceramides) with glucose (Glc, the most common hexose), 
galactose (Gal), mannose (Man), and inositol. 
 Wheat grain has glycosphingolipids with primarily Glc, but also, Man-Glc, [Man]2-Glc and 
[Man]3-Glc headgroups, and has the sphingoid base backbones d18:14, d18:18, d18:2 4,8, t18:0 
and t18:18 with 14:0–26:0 fatty acids (most as -hydroxy fatty acids) (Fujino et al., 1985); rice 
grain has Glc, Man-Glc, Glc-Glc, [Man]2-Glc, Glc-Man-, [Man]3-Glc with d18:0, d18:14 and 
d18:24,8 sphingoid bases and 16:0–24:0 fatty acids (including some -hydroxy fatty acids) (Fujino 
et al., 1985 )  Spinach leaf sphingolipids are comprised of Glc, Cellobiose and Glc-[Man]2-Glc 
with d18:0, d18:18, d18:24,8, t18:0, t18:18 with 16:0–24:0 fatty acids (Ohnishi et al. 1983 ); 
soybean has a single cerebroside, Glc ceramide (GlcCer), with d18:0, d18:14, d18:18, d18:24,8, 
t18:0, t18:18 and 16:0–26:0 fatty acids (including -hydroxy and ,ß-dihydroxy fatty acids) 
(Ohnishi and Fujino, 1982 ); bell pepper and tomato also have mainly GlcCer with d18:24,8, 
d18:18, t18:18 sphingoid bases and 16:0–24:0 (including -hydroxy-) fatty acids (Whitaker, 1996). 
Recent developments in the analysis of sphingolipids by GC/HPLC/mass spectroscopy (MS) and 
tandem mass spectrometry are making it feasible to accurately identify and quantify complex 
sphingolipids (Vesper et al., 1999). 
2.9.4 Dietary Intake of Sphingolipids 
 From Table 2.2 it is evident that dairy products appear to be major sources of 
sphingolipids, followed by meat and fish, eggs, and vegetables; with the contribution from 
vegetables was the most difficult to estimate from available data (Vesper et al., 1999). Yearly per 
capita intake of sphingolipids from the foods in Table 2.2 average 154 mmol, which is equivalent 
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to ~116 g. Estimating fruits and vegetables that contribute as described in footnotes 7 and 8 of 
Table 2.2, add up to 28 mmol, for a total of 181 mmol (139 g) consumed per year. Sphingolipids 
constitute between 0.01 to 0.02% of the diet (by weight). This amount (0.3–0.4 g/d) provides few 
"fat calories" but is comparable with lipids such as cholesterol and tocopherols (Ensminger et al., 
1994). Consumption could vary considerably among individuals who consume foods that are 
particularly rich in sphingolipids (Vesper et al., 1999). 
2.10 Bioavailability of Sphingolipids 
2.10.1 Hydrolysis of Sphingolipids in the Gastrointestinal Tract 
 Sphingomyelin and cerebrosides undergo little cleavage in the stomach, but are hydrolyzed 
in all subsequent regions of the small intestine and colon of rats and mice (Schmelz et al., 1994; 
Nilsson, 1968 and 1969b). The luminal contents of rat small (and large) intestine contain 
substantial sphingomyelinase, glucoceramidase, and ceramidase activities (Nilsson, 1969a and 
1969b). Not all of the ingested sphingolipids are hydrolyzed and absorbed (Vesper et al., 1999). 
Nilsson (1968) reported that ~25% of an administered dose of sphingomyelin was excreted in 
feces, of which 10% was the intact molecule, 80–90% was ceramide, and 3–6% was free 
sphingosine. There is a direct correlation between the amounts of sphingomyelin that is fed vs. 
the amount found in the colon (Nyberg et al., 1998). Germ-free mice show a drastically reduced 
hydrolysis of sphingomyelin, which suggests that intestinal microflora are major contributors to 
sphingolipid turnover in the lower bowel (Duan et al., 1995 and 1996). Similar studies with 
cerebrosides (Nilsson, 1968) found that 43% was excreted, with 40–70% being intact molecule, 
and 25–60% as ceramide. Less it is known about human metabolism of sphingolipids, but human 
pancreatic juices contain a taurocholate-dependent neutral sphingomyelinase (Chen et al., 1992) 
and an alkaline sphingomyelinase has also been detected in human bile (Nyberg et al., 1996). 
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2.10.2 Uptake of Sphingolipids 
 Much of the sphingosine (and ceramide) that is derived from hydrolysis of complex 
sphingolipids is rapidly taken up by intestinal cells and degraded to fatty acids (via fatty 
aldehydes) or reincorporated into complex sphingolipids that remain associated primarily with 
the intestine (Nilsson, 1968; Schmelz et al., 1994). When sphingoid-base–labeled sphingolipids 
were fed to rats, a small amount of the radiolabeled sphingoid base was found in lymph, blood 
and liver, which implies that some component(s) of dietary sphingolipids were transported 
through the mucosa to the systemic circulation (Nilsson, 1968; Schmelz et al., 1994). 
Chylomicrons may be involved in sphingolipid transport because intestinal lymph contains ~1 
nmol/mL of sphingolipid of which about 40% is ceramide (Merrill et al., 1995). 
2.10.3 Transport of Sphingolipids via Serum Lipoproteins 
 Sphingolipids are components of serum lipoproteins. The greatest amounts appear in LDL 
followed by VLDL and then HDL (Merrill et al., 1995). Sphingomyelin is the major sphingolipid 
of LDL and HDL, whereas VLDL contains mainly ceramide. Small amounts of free sphingoid 
bases are present in the blood (Wang et al., 1992), associated with albumin and circulating cells 
(both erythrocytes and leukocytes) (Wilson et al., 1988); sphingosine 1-phosphate is also found 
in plasma and serum, but appears to be derived from platelets (Yatomi et al., 1995) because of its 
high affinity for Edg-1 receptors (Van Brocklyn et al., 1998). 
2.10.4 Cellular Metabolism of Sphingolipids and Regulation of Sphingolipid Biosynthesis 
by Diet 
 
 All organs appear to be capable of de novo sphingolipid biosynthesis (Merrill et al., 1985, 
Nagiec et al., 1996) and there is no evidence that consumption of dietary sphingolipids is 
required for growth under normal conditions. Nonetheless, exogenous sphingolipids are required 
for the growth of mammalian cells with defects in serine palmitoyltransferase (Hanada et al., 
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1992), the initial enzyme of sphingolipid biosynthesis, which establishes that sphingolipids are 
necessary for normal cell function (Vesper et al., 1999). 
De novo sphingolipid synthesis is subject to some degree of feedback regulation. Studies 
using radiolabeled sphingolipids confirmed that sphingoid base backbones that are recovered 
from dietary sphingolipids affect tissue sphingolipid biosynthesis (Mandon et al., 1991; van 
Echten-Deckert et al., 1997). 
2.11 Perspective of Chemoprevention through Diet 
Although targeted therapy is yielding promising results in the treatment of specific 
cancers, drug resistance poses a problem. Acquired drug resistance to chemotherapy occurs after 
primary surgical intervention and subsequent chemotherapy treatments. The majority of patients 
develop disease recurrence, which is due to tumor cell heterogeneity and genetic instability.  
However, endothelial cells show genetic stability and proliferate normally. As endothelial cells 
participate in tumor angiogenesis, developing anti-angiogenic strategies serves as a greater 
benefit in containing tumor development and metastasis (Benouchan and Colombo, 2005). 
Furthermore, recent studies have implicated chemoprevention through diet as a viable 
approach against cancer. There is strong evidence that many daily-consumed dietary compounds 
possess cancer-protective properties that might interrupt the carcinogenesis process (Brenner and 
Gescher, 2005; Chen and Kong, 2005). These properties include the induction of cellular defense 
detoxifying and antioxidant enzymes, which can protect against cellular damage, caused by 
environmental carcinogens or endogenously generated reactive oxygen species. These 
compounds can also affect cell-death signaling pathways, which could prevent the proliferation 
of tumor cells (Chen and Kong, 2005).  
Therefore, focus would be on the response of nutraceuticals or dietary components on 
cancer and tumor progression. It would greatly benefit efforts of supplementing diet as a 
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chemopreventive measure not only against cancer but various degenerative diseases. Our 
approach was in determining the potential of sphingolipids against selected cancers. Our 
hypothesis was based on the literary evidence establishing the role of dietary sphingolipids in 
inhibiting colon cancer and that of sphingosine and ceramide as apoptosis inducing agents.  It 
was evident that sphingolipids participated in the sphingomyelin/ceramide pathway. Changes of 
sphingomyelin metabolism have been found to be associated with tumorigenesis in various 
tissues and a particular link between sphingomyelin metabolism and colon cancer has been 
indicated (Duan, 2005). A study conducted by Lemonnier et al., (2003) on mice fed with 
sphingomyelin before and after tumor initiation determined that sphingolipids were as effective 
in the chemoprevention of tumors as in early intervention.  Our goal was to determine the role of 
sphingolipids in the process of angiogenesis that could prove to be an important characterization 
of sphingolipids in diet and therapeutics. 
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CHAPTER 3.  IN VITRO ANALYSIS OF SPHINGOLIPIDS AS ANTI-ANGIOGENIC 
COMPOUNDS 
 
3.1 Introduction 
Epidemiological studies suggest that about 35% of cancer related deaths are attributed to 
diet with a range of 20 to 60% for various sites (Parodi, 1997). Conversely, there are many 
bioactive compounds readily available in food that can be used as preventive measures towards 
diseases. The evaluation of natural compounds with cancer preventive properties in food is now 
an important element in overall cancer prevention strategies. Sphingolipids are found in many 
foods including milk, cheese, eggs, and soybeans. One liter of milk contains 39-119 mg 
sphingomyelin, 6-11 mg glucosylceramide, 6.5-15 mg lactosylceramide, and ~ 11 mg of 
ganglioside (Vesper et al., 1999). Glycosphingolipids belong to a group of membrane 
components in eukaryotes known as sphingolipids. Sphingolipids are one of the most structurally 
diverse categories of lipid in nature (Berra et al., 2002).  There is indirect evidence suggesting a 
role for dietary sphingolipids in combating colon cancer in humans (Symolon et al., 2004; 
Vesper et al., 1999; Merrill et al., 1997). 
Several studies have demonstrated that the intake of dairy sphingolipids, such as 
cerebroside (glucosylceramide), sphingomyelin, and ganglioside significantly reduce incidence 
of colonic aberrant crypt foci and adenocarcinoma in CF1 mice treated with 1,2-
dimethylhydrazine, and of intestinal adenoma in Min mice (Berra et al., 2002). It was also noted 
that dietary sphingolipids that caused these effects on colon cancer had no deleterious effects on 
the animals. Although no human clinical trials or epidemiological studies have been undertaken 
to elucidate the effects of dietary intake of sphingolipids, it is believed that sphingolipid 
consumption would not cause any adverse toxicological effects (Berra et al., 2002). The role of 
sphingolipids, especially ceramide has been extensively studied as a pro-apoptotic agent in 
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MCF-7 breast cancer cells (Ameyar et al., 1998), and LNCaP and PC3 prostate cancer cells 
(Sumitomo et al., 2002; Kimura et al., 2003).  
The role of sphingolipids in angiogenesis is poorly understood. Kim et al. (2002), 
identified sphingomyelin as the active component for vesicle-induced endothelial cell migration, 
tube formation, and neovascularization. Igarashi et al. (2003), explored the role of VEGF in 
sensitizing the vascular endothelium to the effect of lipid mediators by promoting the induction 
of S1P1 receptors, representing a potentially important point of cross-talk between the receptor-
regulated eNOS signaling pathways in the vasculature. Yabu et al. (2005), determined in an in 
vivo zebrafish model system that thalidomide-induced antiangiogenic action is regulated by the 
balance between ceramide and S1P signal. However the potential role of sphingolipid group with 
respect to the expression of angiogenic factors in various cancer cells needs to be studied to 
determine a possible mechanism with which these compounds would participate in 
neovascularization of the tumor under the influence of normal and depleted oxygen environment 
(hypoxia). Hypoxia plays an important role in tumor angiogenesis. Hypoxia initiates expression 
of hypoxia inducing factors such as HIF-1α subunit. Pugh and Ratcliffe (2003), suggested that 
HIF-1α induces upregulation of several angiogenic factors including VEGF. It is therefore 
imperative to study the effect of sphingolipids on HIF-1α translocation.  
 To examine the effect of the sphingolipids on angiogenesis, we selected biomarkers that 
play an important role in initiation of angiogenesis in pathological as well as physiological 
conditions. The biomarkers chosen for the study of angiogenesis were VEGF, Cathepsin-D and 
HIF-1α. The expression of these biomarkers were examined under conditions of normoxia as 
well as hypoxia. Vascular endothelial growth factor (VEGF) is the major endothelial-cell 
specific stimulatory factor and is regarded as the most important positive regulator of 
angiogenesis and vascular permeability. It participates in crucial biological processes, including 
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wound repair and tumorigenesis. The elevated expression of VEGF and its receptors has been 
found in tumor malignancies and has being associated with metastasis formation and poor 
prognosis (Chodorowska et al., 2004). Cathepsin-D is an aspartic protease enzyme, which is 
synthesized in the endoplasmic reticulum, and belongs to the group of lysozymal hydrolases 
(Kokkonen et al., 2004). Many cancer cells have increased amounts of cathepsin B and D in the 
extracellular space, which influences matrix degradation and tumor cell invasion through 
proteolytic cascades. Individual proteases have distinct roles in tumor growth, invasion, 
migration and angiogenesis (Koblinski et al., 2000). Hypoxia-inducible factor-1 (HIF-1) is a 
dimeric transcriptional complex that has been recognized primarily for its role in the 
maintenance of oxygen and energy homoeostasis (Heather et al., 1998). HIF-1 increases the 
transcription of several genes for proteins that promote blood flow and inflammation, including 
vascular endothelial growth factor (VEGF), heme oxygenase-1, endothelial and inducible nitric 
oxide synthase (NOS) and cyclooxygenase-2 (COX-2). Both the hypoxic and the cytokine-
induced activation of HIF-1 involve the phosphatidylinositol- 3-kinase (PI3K) and the mitogen-
activated protein kinase (MAPK) signaling pathways (Hellwig-Burgel, 2005). The study on the 
effects of sphingolipids on the chosen biomarkers of angiogenesis would therefore lead us to 
establish the role of sphingolipids as anti-angiogenic compounds. Thus implying the 
consumption of milk would be a preventive measure against progression of cancer. Further, the 
presence of sphingolipids in dietary sources especially in milk would substantiate them as 
nutraceuticals with health benefits. 
3.2 Materials and Methods 
3.2.1 Cell Harvesting  
HEL 299 normal human lung fibroblast cell, MCF-7 breast, Caco-2 colon, and DU-145 
prostate cancer cells were obtained from American Type Culture Collection (Rockville, MD) and 
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harvested in a continuous culture as per the ATCC procedure.  The growing medium consisted of 
MEM (EBSS) + 10% FBS + 1 mM Na+ pyruvate. The cells were passaged once per week at a 
split of 1:2 and reffed once per week. The cells were then grown as a monolayer.  They were 
attained at 80% confluence.  The cells were raised under both hypoxic and normoxic conditions. 
Hypoxia was maintained by addition of 20 µM CoCl2 to deplete the cell of oxygen availability 
(Lee et al., 2003).  The cells were also serum starved for 24 h before treatment.  
3.2.2 Compound Treatment 
  N-Hexanoyl-D-erythro-Sphingosine (C6-Ceramide, Cer); (2S,3R,4E)-2-
acylaminooctadec-4-ene-3-hydroxy-1-Phosphocholine (Sphingomyelin, SPM); and D-Glucosyl-
ß1-1'-N-Dodecanoyl-D-erythro-Sphingosine (C12 ß-D-Glucosyl Ceramide, GlcCer) were 
purchased from Avanti Polar Lipids (Alabaster, AL). DMSO was used as a carrier solvent for 
C6-ceramide and C12 ß-D-glucosylceramide, whereas ethanol was used to solubilize 
sphingomyelin. The compounds, at a dosage concentration of 0-100 μM, were prepared in 
appropriate solvents for the cell proliferation assay.  The cells were treated at a concentration of 
50 μM and incubated for 48 h at 37° C and 5% CO2 for determining VEGF, cathepsin-D and 
HIF-1α expression. After compound exposure and incubation, the media was sampled to 
determine the level of VEGF. The cells were then trypsinized and subsequently lysed. The 
fractions were then centrifuged at 14000 x g, to separate cytoplasmic and nuclear factor. The 
protein concentrations in each fraction were normalized and cytoplasmic factor was used for 
examining the cathepsin-D expression while nuclear factor was used to determine if HIF-1α 
translocated.   
3.2.3 Cell Proliferation Assay 
After compound treatment and incubation, the viability of cells was measured using 
ViaLight TM HS (BioWhittaker Lab, Rockland, ME). The cells were treated with nucleotide 
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releasing reagents and subsequently treated with nucleotide monitoring reagent as described in 
the manufacturer’s protocol.  The luminescent signal generated by the enzyme luciferase, which 
catalyzes the formation of light from ATP and luciferin, was measured using a Perkin Elmer LS 
50B luminometer.  The result was derived as an ATP concentration, which was used to 
determine the amount of apoptosis.  
3.2.4 Cell Migration Assay 
In this assay, the principle of the Boyden chamber was utilized.  The cells were 
trypsinized and resuspended in a serum free media.  They were then added into a migration 
chamber consisting of a gelatin membrane obtained from Chemicon Quantitative Cell Migration 
(QCM TM, catalog number ECM 510).  The migration chamber was inserted into the feeder tray 
consisting of 10% FBS as chemoattractant.  The cells in the microplate were treated with the 
compound and incubated for 24 hours at 37° C and 5% CO2.  The migration chamber was then 
removed and lysis/dye solution was added to the feeder tray.  The fluorescence was then 
measured at 480/520 nm. 
3.2.5 Cathepsin-D Expression 
The cytoplasmic factor and biotinylated detector antibody (rabbit polyclonal) were 
pipetted into the wells and allowed to incubate simultaneously for 4 hours at 37° C.  This 
allowed binding of the antigen by the capture-antibody as described by the Cathepsin D assay kit 
(EMD Biosciences, Inc. CA).  The amount of detector antibody bound to the antigen was then 
measured by binding it with a streptavidin/horseradish peroxidase conjugate, which catalyzed the 
conversion of the chromogenic substrate TMB from a colorless solution to a blue solution.  The 
color was quantified by spectrophotometry. This indicates the amount of Cathepsin-D protein in 
the sample when compared to the standards. 
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3.2.6 VEGF Expression 
Pre-coated mouse monoclonal antibodies generated against human VEGF were used to 
capture human VEGF using ChemKine TM ELISA protocol in a media from the treated cells. 
Biotinylated VEGF specific rabbit polyclonal antibodies was used to detect VEGF in the sample. 
The VEGF standard provided by the manufacturer was used to plot a standard curve. The assay 
was visualized using a streptavidin alkaline phosphatase conjugate and a chromogenic substrate 
reaction.  The amount of VEGF detected in each sample was compared to a VEGF standard 
curve, which demonstrated a direct relationship between optical density (OD) and cytokine 
concentration.  The higher the OD, the higher the cytokine concentration in the sample, and thus 
higher VEGF.  
3.2.7 HIF-1α Expression 
The extracted nuclear factor from the treated cells was analyzed for HIF-1α  levels using 
sandwich immunoassay TransAM HIF-1 Transcription factor assay kit (Active Motif, CA) by 
capturing HIF-1α with mouse monoclonal antibody as per the manufacturers guidelines and 
quantitated using streptavidin coated-HRP conjugate and diaminobenzidin as substrate. The 
reaction was visualized spectrophotometrically at 450 nm.  
3.2.8 Statistical Analysis 
Statistical analysis was performed by Student's t-test or, where appropriate, by one-way 
analysis of variance (ANOVA) followed by Newman-Keuls test for significance. Differences 
were considered to be statistically significant when P<0.05. Within group comparison were 
determined by LSD post-hoc analysis. 
3.3 Results and Discussion 
3.3.1 Cell Viability Assay 
Under normoxic conditions the effect of C6-ceramide (Cer) on the HEL 299 (normal lung 
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cell lines) had a proliferative effect whereas sphingomyelin (SPM) and C12 ß-D-
Glucosylceramide (GlcCer) caused a reduced proliferation in a dose dependent manner (Figure 
3.1 A-B). MCF-7 cell lines showed an increased proliferation when exposed to compound 
(Figure 3.1 C-D). Colon cancer cells (Caco-2) showed significant reduction in the cell viability 
with SPM exposure under 1 μM and gradually increased to 93 % at 50 μM and reduced to (72 
%) at 100 μM (Figure 3.1 E-F). C6-ceramide and GlcCer caused lower proliferation at 
concentrations ranging from 0.05-0.1 μM as against higher proliferation at concentrations 
ranging from 0.2-25 μM. In DU-145 cells, SPM had an anti-proliferative effect at the 
concentration tested, while Cer and GlcCer increased the cell viability (Figure 3.1 G-H). 
Under HIF induced conditions for MCF-7 breast cancer cells, GlcCer showed reduced 
cell viability at concentrations ranging from 10-100 μM, with the lowest being at a concentration 
of 10 μM (Figure 3.2 A-B). C6-ceramide caused higher proliferation from 0-50 μM but was 
significantly reduced at 100 μM to 75 % of cell survival.  Colon cancer cells (Caco-2) treated 
with SPM had reduced cell viability when compared to Cer and GlcCer. C6-ceramide treated 
cancer cells showed significantly higher cell proliferation than GlcCer (Figure 3.2 C-D). Prostate 
cancer cells   (DU-145) had very low cell viability when exposed to Cer, SPM and GlcCer at the 
concentration of 2 µM. The reduction in cell viability was 48%, 84% and 45%, respectively, with 
increased cell proliferation at higher concentrations (Figure 3.2 E-F). 
The cell proliferation observed for Cer treated cells can be caused by hydrolysis of Cer to 
sphingosine 1-phosphate or by glucosylation of Cer, which are known to induce cell proliferation 
(Radin, 2003). In a study conducted by Cuvillier and Levade 2001, on human leukemia cells, 
they proposed that S1-P likely exerts its inhibitory effect on apoptosis through a mechanism 
upstream of the mitochondrion.  
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Figure 3.1 Cell Viability of Compounds Treated at Concentrations of 0-100µM Under Normoxic 
Conditions.  
A-B. HEL 299 Normal Lung Fibroblast Cells; C-D. MCF-7 Breast Cancer Cells; E-F. Caco-2 
Colon Cancer Cells; G-H. DU-145 Prostate Cancer Cells. 
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Figure 3.2 Cell Viability of Compounds Treated at Concentrations of 0-100µM Under HIF-1α 
Induced Conditions.  
A-B. MCF-7 Breast Cancer Cells; C-D. Caco-2 Colon Cancer Cells; E-F. DU-145 Prostate 
Cancer Cells. 
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S1-P co-treatment inhibited the translocation of the mitochondrial key proteins cyt c and 
Smac/DIABLO to the cytoplasm. Thus promoting the induction of apoptosis by stimulation of 
the cell surface Fas and TNF-α death receptors, by serum deprivation. This was also achieved by 
addition of exogenous ceramides in human acute leukemia cells. They hypothesized that 
sphingosine kinase (SphK) activity is likely to be involved in clearing the cell of sphingosine and 
ceramide, both of which have proapoptotic functions, thus tilting the balance toward survival. 
Another study established that Bcl-2 inhibited ceramide-induced death, but not ceramide 
generation. In contrast, Cytokine response modifier A (CrmA), a potent inhibitor of Interleukin-
1β converting enzyme and related proteases, inhibited ceramide generation and prevented TNF-
α-induced death. Exogenous ceramide could overcome the CrmA block to cell death, but not the 
Bcl-2 block (Dbaibo et al., 1997). Conversely, exogenous SPM can stimulate SMase to elevate 
Cer. GlcCer on the other hand, rapidly hyrolyzes to Cer by the action of GlcCer glucosidase, 
which helps cause the cell to undergo apoptosis.   
Overall, it can be implied that the effect of Cer on cancer cells was cytostatic whereas 
SPM showed inhibitory activity in most of the cancer cells. The effect of Cer can be attributed to 
its effect on the cell cycle rather than having a direct impact on the death-signaling pathway of 
the cancer cell. More research is needed to confirm the role of Cer on the cell cycle. 
3.3.2 VEGF Levels 
The VEGF expression for normal lung cancer cells did not show any major increase with 
the exposure of the compounds under study (Figure 3.3-A). This is reasonably anticipated as 
normal cells do not show substantial levels of VEGF and therefore the exposure of compounds 
do not result in altered VEGF levels. However cancer cells, due to its abnormal expression of 
growth factors may exhibit increased response to compound exposure.  The C6-ceramide treated 
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cells, however had a significantly higher VEGF expression than the control.  MCF-7 cells under 
normoxic conditions had lower expression under the influence of Cer but had no significant 
effect under GlcCer or SPM, whereas, hypoxic MCF-7 cells had lower VEGF expression under 
C6-ceramide and GlcCer, while SPM did not affect the VEGF expression (Figure 3.3-B). 
Caco-2 normoxic cells did not upregulate the VEGF expression with respect to Cer and GlcCer 
exposure but showed an increased level of VEGF with SPM (Figure 3.3-C). DU-145 cells under 
normoxic conditions had very low expression of VEGF with respect to all the compounds. 
Hypoxia induced DU-145 cells had VEGF expressions under the influence of GlcCer and SPM, 
but Cer did not have any effect on the VEGF expression (Figure 3.3-D). It is noteworthy that 
DU-145 hypoxia treated cells had comparatively lower VEGF expression than hypoxia induced 
cells. Also, contrary to the Caco-2 results, normoxic DU-145 cells showed lower expression of 
VEGF when exposed to all the compounds. 
3.3.3 Cathepsin-D Expression 
SPM and GlcCer exposed normal cells (HEL 299), MCF-7, and Caco-2 (normoxic and 
hypoxic) had significantly lower Cathepsin-D expression while Cer increased the levels of 
cathepsin-D (Figure 3.4-A). This is in agreement with the established role of ceramide, which 
specifically binds to and activates the endosomal acidic aspartate protease cathepsin D. Direct 
interaction of ceramide with cathepsin D results in autocatalytic proteolysis of the 52 kDa pre-
pro cathepsin D to form the enzymatically active 48/32 kDa isoforms of cathepsin D (Heinrich et 
al., 2000).  The best result of lower cathepsin-D expression was observed with GlcCer in MCF-7, 
Caco-2 and DU-145 (Figure 3.4-B, 3.4-C, 3.4-D). SPM had lower expression of cathepsin-D in 
hypoxic conditions. Cer only proved effective on the DU-145 treated cells under both normoxic 
as well as hypoxia induced conditions. 
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Figure 3.3 VEGF Expression in Cells Exposed to Sphingolipids at a Concentration of 50 µM 
Under Normoxic and Hypoxic Conditions.  
A. HEL 299 Normal Lung Fibroblast Cells; B. MCF-7 Breast Cancer Cells; C. Caco-2 Colon 
Cancer Cells; D. DU-145 Prostate Cancer Cells. 
a Significantly different from Control under normoxic conditions. 
b Significantly different from Control under HIF-1α induced conditions. 
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Figure 3.4 Cathepsin-D Expression in Cells and Cancer Cells Exposed to Sphingolipids at a 
Concentration of 50 µM Under Normoxic and Hypoxic Conditions.  
A. HEL 299 Normal Lung Fibroblast Cells; B. MCF-7 Breast Cancer Cells; C. Caco-2 Colon 
Cancer Cells; D. DU-145 Prostate Cancer Cells. 
 
a Significantly different from Control under normoxic conditions. 
b Significantly different from Control under HIF-1α induced conditions. 
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3.3.4 Cell Migration Assay 
All compounds induced cell migration in HEL 299 (Control) cells (Figure 3.5-A). 
Although this result could be specific for cell culture study, normal cells existing in tissues do 
not exhibit migration under external stimuli. In the case of cancer cell lines, C6-ceramide 
induced cell migration in Caco-2 cells under both conditions, whereas it did not affect cell 
migration in MCF-7 (normoxic) cells. C6-Ceramide significantly reduced migration under MCF-
7 cells in hypoxic conditions and DU-145 under normoxic and hypoxic conditions (Figure 3.5-B, 
3.5-C, 3.5-D).  Sphingomyelin had no significant effect on MCF-7 cell migration but reduced the 
migration of Caco-2 under both conditions and DU-145 cells under normoxic conditions. 
Glucosylceramide did not affect the MCF-7 cell migration but affected the migration of Caco-2 
(normoxic and hypoxic) and DU-145 under normoxic conditions. It is noteworthy that with 
MCF-7 cells, which are highly metastatic, the effect seemed to be less with treatment of all the 
compounds, except for ceramide treated to hypoxic MCF-7 cell, which reduced the cell 
migration. 
3.3.5 HIF-1α Expression 
 As HIF-1α is predominantly expressed in response to hypoxia, our results clearly 
demonstrated significantly high amounts of HIF-1α in hypoxic treated cells (Figure 3.6-A, 3.6-
B, 3.6-C, 3.6-D). Except for Cer exposure of Caco-2 cell, all the compounds under study 
exhibited significant reduction in HIF-1α expression when treated in hypoxic medium.This is 
desirable since HIF-1α regulates the transcription of mitogenic growth factors associated with 
angiogenesis under hypoxia. The suppression of hypoxia by sphingolipids would cause cells to 
activate pro-angiogenic factors and subsequently restrict the availability of nutrients and oxygen 
to sustain the survival and induce apoptosis.   
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Figure 3.5 Cell Migration in Cancer Cells Exposed to Sphingolipids at a Concentration of 50 
µM Under Normoxic and Hypoxic conditions.  
A. HEL 299 Normal Lung Fibroblast Cells; B. MCF-7 Breast Cancer Cells; C. Caco-2 Colon 
Cancer Cells; D. DU-145 Prostate Cancer Cells. 
 
a Significantly different from Control under normoxic conditions. 
b Significantly different from Control under HIF-1α induced conditions. 
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Figure 3.6 HIF-1α Expression in Cancer Cells Exposed to Sphingolipids at a Concentration of 
50 µM Under Normoxic and Hypoxic Conditions.  
A. MCF-7 Breast Cancer Cells; B. Caco-2 Colon Cancer Cells; C. DU-145 Prostate Cancer 
Cells. 
 
a Significantly different from control under normoxic condition. 
b Significantly different from control under HIF-1α induced condition. 
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3.4 Conclusion 
 
Breast cancer MCF-7 cells treated with Cer had significant effect on the cell death at 
higher concentrations with lower VEGF expression compared to GlcCer and SPM. The levels of 
cathepsin-D were higher in Cer treated cell, which explains the higher cell viability compared to 
the rest of the compounds. The cell migration was similar under normoxic conditions but 
reduced under hypoxic conditions. Cathepsin-D expression under SPM treated MCF-7 cells was 
significantly lower under both conditions than control. GlcCer had significant apoptotic activity 
on hypoxic MCF-7 cells. Also, the cathepsin-D and HIF-1α were significantly reduced under 
hypoxic conditions.  
Colon cancer cells (Caco-2) treated with Cer had reduced cell growth at > 50 μM under 
normoxic as well as hypoxic conditions. Cathepsin-D, cell migration and HIF-1α expression 
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were significantly reduced under hypoxic condition. SPM had low cathepsin-D levels, cell 
migration in normoxic and hypoxic conditions as well as low HIF-1α at hypoxic condition. In 
GlcCer treated cells, the levels of cathepsin-D expression, and cell migration were reduced under 
normoxic as well as hypoxic conditions. 
Prostate cancer cells (DU-145) exposed to SPM had reduced cell viability. All the 
compounds had lower levels of VEGF expression under normoxic conditions at 50 μM exposure; 
only GlcCer had lower VEGF expression under hypoxic condition. Cathepsin-D levels were 
significantly reduced under both conditions for all the compounds. Cell migration was reduced 
under normoxic condition and also for cells exposed to Cer under hypoxic condition. The HIF-
1α was significantly reduced in all the compounds treated.  
It can be interpreted from the results that different cell-lines under different conditions 
responded distinctly to the three compounds under investigation. Various cancer cells have been 
known to have abnormal activities of the enzymes involved in the ceramide de novo pathway. 
Knowing the activity of each enzyme in specific cancer cell-lines would shed light on designing 
specific/combination of sphingolipids in diet composition to facilitate homeostasis or induce 
apoptosis in those relevant cancer cells or to act as a chemopreventive bioactive agent in a 
normal diet. 
The results show the importance of diet based sphingolipids role in preventing cancer 
progression by inhibiting angiogenesis. It has been demonstrated that all the compounds under 
investigation had distinctive effect on different cancer cell-lines and the process with which they 
inhibit angiogenesis. This implies that, appropriate diet can be recommended or formulated to 
prevent cancer and other chronic diseases. 
 76
CHAPTER 4.  IN VIVO ANALYSIS OF SPHINGOLIPIDS AS ANTI-ANGIOGENIC 
COMPOUNDS 
 
4.1 Introduction 
 
The study of angiogenic process and the development of therapeutic agents to inhibit, or 
stimulate angiogenesis involves a wide range of in vivo assays. These assays vary depending 
upon their quantitative nature, difficulty, rapidity and cost (West et al., 2001). The most 
commonly used in vivo angiogenesis assay is the chorioallantoic membrane (CAM) assay. The 
main advantages of the CAM assay is its low cost, simplicity, reliability, and large scale 
screening capabilities. However, the disadvantages of CAM is that it already contains a well-
developed vascular network and the vasodilation may be hard to distinguish from the effects on 
vascularization by the test substance to that caused due to its manipulation during 
experimentation. Also, it undergoes nonspecific inflammatory reactions due to hyperplastic 
reactions of the chorion epithelium (Ribatti et al., 2000). Another in vivo model that has gained 
acceptance recently is the zebrafish assay. Zebrafish has long been an accepted model for studies 
of vertebrate developmental biology. The zebrafish vasculature system is highly conserved and 
blood vessel formation by angiogenic sprouting requires the same proteins that are necessary for 
blood vessel growth in mammals (Isogai et al., 2001; Vogel and Weinstein, 2000).  The 
advantages of the zebrafish assay are rapid screening, use of large number of embryos for 
quantitative measurement, and ease of maintenance and replication (Serbedzija et al., 1999).  
Based on the in vitro results, our aim was to perform the in vivo assessment to 
qualitatively establish the role of sphingolipids under physiological conditions. We examined the 
effect of the selected compounds namely Cer, SPM and GlcCer in the in vivo angiogenesis 
models such as CAM and zebrafish.  
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4.2 Materials and Methods 
 
4.2.1 Chorioallantoic Membrane (CAM) Assay  
Fertilized white broiler eggs were obtained from Spafas (Roanoke, IL) and the outside of 
the shells were washed with 70% ethanol. The eggs were then incubated at 37°C for 3 days and 
rotated 180 degrees three times daily. After incubation, the eggs were then cleaned with 70% 
ethanol and cracked, and the embryos were explanted into sterile Petri dishes and incubated for 
two days at 37°C and 5% CO2.  
4.2.1.1 Compound Delivery  
DMSO, Cer, SPM, and GlcCer at a concentration of 50 µM was applied to 5mm nylon 
mesh and freeze dried for 24 h. The mesh was then placed on an outer third of the CAM and the 
Petri dish was returned to the humidified chamber and incubated for 24h of growth before 
examination by image analysis. 
4.2.2 Zebrafish Assay 
4.2.2.1 Embryo Collection 
Embryos were generated by natural pair-wise matings, as described in the zebrafish 
handbook (Sprague et al., 2001). For each mating, 4-5 pairs were set up and an average of 100-
150 embryos per pair were generated. Embryos were maintained in embryo medium (0.2 g/l of 
Instant Ocean Salt in distilled water) at 27-28 °C for approximately 10h before sorting for 
viability, using both morphology and developmental stage as criteria. Healthy embryos were then 
dechorinated by enzymatic digestion with 1.4 mg/ml protease (Sigma, St. Louis, Missouri, USA) 
for 7-8 min at room temperature. The dechorinated embryos were then washed at least ten times 
in embryo water. Because the fish receives nourishment from an attached yolk sac for the 
duration of the experiment, no additional nutritional maintenance was required. 
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4.2.2.2 Compound Addition 
DMSO, Cer, SPM, and GluCer were added directly to the embryonic media in which the 
fish swim. The chemical was added to the media at 10-14 hours post fertilization (hpf), before 
angiogenic vessels express Flk-1 (~19 hpf). The number of embryos per treatment is included in 
Table 4.1 and Table 4.2.  
4.2.2.3 Visual Screen 
After compound addition, the embryos were maintained in individual Petri dishes at 27-
28°C until 48-72 hpf. Embryos were visually inspected for viability, gross morphological 
defects, heart rate and circulation. Circulation was assayed by visually comparing the movement 
of blood cells in treated and control embryos to assess the relative flow rate. The embryos were 
visually inspected every six hours following compound treatment until 36 hpf and then 
monitored every hour until 56 hpf to notice the ISV blood circulation which usually starts 
between 36-48 hpf and is complete by 56 hpf. Each embryo in a Petri dish was videotaped using 
a camera mounted on a Brightfield dissecting microscope. 
4.2.2.4 Morphological Techniques: Nervous System-Staining 
Whole mount immunohistochemistry was carried out using a modified version of a 
previously published protocol; Svoboda et al., 2001 & 2002. Embryos processed for 
immunohistochemistry were first fixed in 4% paraformaldehyde overnight at 4oC and then stored 
in PBS. After permeablization, they were incubated in a primary antibody overnight at 4oC. The 
primary antibody znp1 was used at a dilution of 1:250. The following day, the embryos were 
washed for 60 minutes in PBS buffer and then incubated in a fluorescent secondary antibody, 
Alexa 546 (1:1000 dilution) for 90 minutes. They were then rinsed in PBST for another 60 
minutes and prepared for image analysis. Images of stained embryos were digitally captured 
with the aid of a Hammamatsu digital camera mounted to a Zeiss (Mot 2) inverted microscope. 
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4.2.2.4 GFP-labeled transgenic zebrafish 
Intersegmental vessels (ISVs) patterning was observed using Fli-GFP-labeled transgenic 
zebrafish. Fli-1 is an endothelial marker and GFP labeling on Fli-1 promoter aids in the 
observation of vasculature structure formation of zebrafish during embryogenesis. For examining 
primary motor neurons formation, NBT-GFP labeled transgenic zebrafish were used. In NBT 
transgenic fish, GFP can easily be detected in both CaP and MiP motor neuron axons. Both, 
DMSO and ceramide were exposed to the transgenic fish between 10-12 hpf and images were 
acquired at 48 hpf. The GFP filter cube on the microscope was used to acquire the GFP 
fluorescent signal.  
4.3 Results and Discussion 
4.3.1 Chorioallantoic Membrane (CAM) Assay  
DMSO, which was used as a carrier, when exposed on the chicken CAM, had a modest 
effect on the vasculature. It attenuated blood vessel formation within 24 h of exposure. However 
the observation of the effect of DMSO to that of the other compounds in this study were distinct 
(Figure 4.1 A-B). The C6-ceramide tested on chicken CAM affected blood vessels within 24 h 
(Figure 4.1 C-D). Longer exposure was deleterious to the embryo. The chicken embryo died 
within 36-48 h of age. SPM had significant vascular growth, but the vessels looked dilated and 
newly formed vessels were seen sprouting from the blood vessel within 24h of exposure. 
It is likely that SPM affected the vascular smooth-muscle vessels or made the basement 
membrane more permeable (Figure 4.1 E-F). GlcCer regressed the formation of a large number 
of vessels (Figure 4.1 G-H). There was a complete loss of sprouting in 24 h treated area of the 
embryo as against the untreated area where vasculature was normal. SPM and GlcCer were non-
toxic and the embryo survived during the exposure time. 
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Figure 4.1 Chorioallantoic Membrane (CAM) Assay for Angiogenesis 
A-B: DMSO treated region, A-0 h and B-24 h; C-D: Cer treated region, C- 0h and D-24 h; E-F: 
SPM treated region, E-0h and F-24h; G-H: GlcCer treated region, G-0h and H-24h. 
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Table 4.1 Analysis of 2-day Old Larvae in Trunk Region for Intersegmental Vessel (ISV) Patterning for Embryos Treated with 
DMSO and Cer 
48-54 hpf 
Survival Observations Abnormal 
Compound Dosage Zebrafish 
type 
Exposure 
Stage 
(hpf) (N) normal no 
circulation 
disrupted 
circulation 
 
Blood 
circulation 
affected 
(%) 
0.8% HuC 10-14 21 18 1 1 1 14 
 NBT 14 12 11 0 1 0 8 
DMSO 
 MTAB 10-12 35 31 2 2 0 11 
  FLI 10-12 4 4 0 0 0 0 
DMSO  Total 10-14 72 64 3 4 1 11 
400 µM HuC 10-14 22 8 0 14 0 64 
 NBT 14 7 0 1 6 0 100 
Cer 
 MTAB 10-12 68 25 0 43 0 63 
  FLI 10-12 24 4 0 18 0  
Cer  Total 10-14 121 37 1 81 0 69 
 
Table 4.2 Analysis of 2-day Old Larvae in Trunk Region for Intersegmental Vessel (ISV) Patterning for Embryos Treated with 
Ethanol, SPM and GlcCer 
48-54 hpf 
Survival Observations Abnormal 
Compound Dosage Zebrafish 
type 
Exposure 
Stage 
(hpf) (N) normal no 
circulation 
disrupted 
circulation 
 
Blood 
circulation 
affected 
(%) 
EtOH 0.8% MTAB 12 13 4 0 9 0 69 
SPM 60 µM MTAB 12 31 6 0 25 0 81 
GlcCer 100 µM MTAB 12 4 1 0 3 0 75 
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4.3.2 Zebrafish Angiogenesis Assay 
The intersegmental vessels (ISVs) in zebrafish are arranged in an extremely regular 
pattern. In the medial-lateral plane, the ISVs run between the notochord and somite ventrally, 
while they are restricted between the neural tube and somite boundaries in the dorsally (Childs et 
al., 2002). Intersegmental artery and intergemental veins connect ventrally to either dorsal aorta 
or posterior cardinal vein, respectively (Figure 4.2-A) and run dorsally between and adjacent to 
the notochord and neural tube and the somites (Isogai et al., 2003). 
Three primary motor neurons develop in the ventral spinal cord and have been 
individually identified as the caudal primary (CaP), middle primary (MiP), and rostral primary 
(RoP) neurons. Additionally, a fourth motor neuron called variable primary neuron (VaP), also 
develops adjacent to the CaP neuron, but only in some segments (Eisen et al., 1989). Ultimately, 
the VaP motor neurons die round 24hpf. 
The axons of the primary motor neurons have been shown to follow specific trajectories 
to the periphery (Hjorth and Key, 2002; Lewis and Eisen, 2003). The pioneer motor neurons of 
zebrafish spinal cord develop at 15 hpf and extend axons at approximately 17 hpf. The CaP axon 
pioneers the common pathway of motor axons to the horizontal myoseptum separating the dorsal 
and ventral myotomes. CaP axons extend into ventral somite after contacting the muscle pioneer 
cells (Figure 4.2-B). The most ventral extension of CaP axons is believed to be dependent on 
restricted expression of semaZ1b, a ligand within the posterior portion of the somite. It is 
repulsive to CaP axon growth cones (Hjorth and Key, 2002). The MiP axons project dorsally into 
the peripheral muscle mass.  The ability of zebrafish to tolerate the solvent was considered and 
no morphological changes were observed at 1% DMSO.  Based on the solubility criteria and 
effective dose concentration of Cer, a working dose concentration of 0.8% DMSO as a carrier 
solvent was finalized. 
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Figure 4.2 Illustrations of Zebrafish Mid-trunk Region  
(A) Schematic diagram of ISVs (ISA: Intersegmental artery; ISV: Intersegmental vein; DLAV: 
dorsal longitudinal anastomotic vessel). Intersegmental vessels are indicated by arrows. ISVs are 
represented with white arrows and blood cells are represented with black arrows; (B) Schematic 
diagram of a lateral view showing ventral CaP (blue) and dorsal MiP (red) axon trajectories. 
Anterior is to the left, dorsal is up. 
Anterior is to the left, dorsal is up. Blood flow caudally (to the right) via the dorsal aorta (DA), 
and returns rostrally (to the left) via post cardinal vein (PCV). 
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Earlier studies with labrasol as solvent at concentrations of 1.0 and 0.1% had a paralytic 
effect on the embryo. Preliminary studies were conducted with Cer dose ranging from 100 μM to 
400 μM. The intended phenotype was observed on exposure concentration of 400 μM.  
4.3.3 Morphological Assessment of Zebrafish 
Zebrafish embryos at the 10-14 hpf stage were incubated with Cer at a concentration of 
400 μM. Treatment of Cer up to 80 hpf caused loss of blood flow in 69% of zebrafish (Table 
4.1). During treatment, embryos were mobile and responsive to external stimuli. Except 
disrupted blood flow through ISVs no other deleterious effects were observed. There were no 
observable morphological changes observed in the embryos treated under two conditions (Figure 
4.3). However, there was a distinctive loss of blood flow due to constricted ISVs (Figure 4.4-B, 
vessel b) in Cer  treated embryos at 48 hpf compared to the controls treated with 0.8% DMSO 
(Figure 4.4-A). When the Cer exposure was removed and replaced with embryonic media after 
56 hpf,  the blood flow was distinctively different than the controls (Figure 4.4-C) when 
observed between 72-80 hpf (Figure 4.4-D).  Blood flow through the ISVs in ethanol and SPM 
treated embryos did not start until 54 hpf when compared to DMSO treated sample (usually 
between 48-52 hpf).  
SPM treated zebrafish embryo showed aberrant blood flow when observed between 48-
72 hpf and had broadened vessels at the choicepoint in the mid-trunk regions as seen in Figure 
4.4-E (vessel b). The effect on ISV blood vessel disruption by ethanol and SPM treated embryos 
were 69% and 81%, respectively (Table 4.2). GlcCer affected the survival of the embryos as only 
20% of the treated embryos survived until 80 hpf (Table 4.1). The vasculature of the ISVs was 
constricted (Figure 4.4-F) and aberrant with GlcCer having 75% embryos affected with abnormal 
ISVs (Table 4.2). The GFP-labeled ISVs showed aberrant ISV formation in Cer treated 
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Figure 4.3 Morphological Observation of Zebrafish Embryo at 40 hpf 
DMSO treated embryos are represented in A, C, E, and G; Cer treated embryos are represented 
in B, D, F, and H. A-B: whole embryo; C-D: anterior (forebrain, midbrain, hindbrain, eye and 
heart (represented with arrow)); E-F: mid-trunk region; G-H: posterior (tail-region). 
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Figure 4.4 Intersegmental Vessel (ISV) Patterning in the Mid-trunk of Zebrafish Embryo.  
(A) DMSO treated embryo at 48 hpf; (B) Cer treated embryo at 48 hpf; (C) DMSO treated 
embryo at 72 hpf; (D) Cer treated embryo at 72 hpf (E) SPM treated embryo at 72 hpf; (F) 
GlcCer treated embryo at 72 hpf. 
Anterior is to the left, dorsal is up. Blood flow caudally (to the right) via the dorsal aorta (DA), 
and returns rostrally (to the left) via post cardinal vein (PCV). 
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Fig. 4.4-A 
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Fig. 4.4-C 
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Figure Contd… 
 90
 
 
Fig. 4.4-E 
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Figure 4.5 GFP-labeled Intersegmental Vessels (ISV) Cross-section of Transgenic Zebrafish. 
A. DMSO treated zebrafish; B-D. Cer treated zebrafish 
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Figure 4.6 GFP-labeled Dorsal Longitudinal Anastomatic Vessels (DLAV) Cross-section of 
Transgenic Zebrafish. 
A. DMSO treated Zebrafish; B-D. Cer treated zebrafish 
 
transgenic zebrafish. Compared to DMSO treated transgenic zebrafish (Figure 4.5-A), Cer 
treated transgenic zebrafish ISVs were observed to be attenuated (Figure 4.5-B), some were 
stunted (Figure 4.5-C) and others were observed to have patterning defects (Figure 4.6-D). Also, 
The DLAV in Cer treated zebrafish was observed to be constricted as shown in figure 4.6-B. 
4.3.4 Znp-1 Staining 
We conducted antibody staining with znp-1 to mark MiP and CaP primary motor neuron 
axons in zebrafish. The primary motor neuron axonal trajectories were affected in Cer exposed 
embryos as shown in Figure 4.7-B compared to DMSO treated embryos (Figure 4.7-A) C6-
Ceramide exposed embryos displayed aberrant primary motor neuron and axonal trajectories. In 
Cer treated embryos, CaP axon guidance was impaired in the ventral somite region as seen in 
Figure 4.7-D. Also, MiP motor axons developed ectopic branches (Figure 4.7-F, 4.7-G), which  
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Figure 4.7 Znp-1 Antibody Staining of DMSO and Cer Treated Zebrafish Embryo.  
(A) DMSO treated embryo at 32X magnification; (B) Cer treated embryo at 32X magnification; 
(C) DMSO treated embryo at 20X magnification with traced trajectories at the bottom; (D) Cer 
treated embryo at 20X magnification with traced trajectories at the bottom; (E) DMSO treated 
embryo at 40X showing CaP trajectory; (E, F) Cer treated embryos with branched CaP axon, 
trajectory traced at the bottom of the figure; (G) DMSO treated GFP-labeled NBT mutant 
zebrafish showing primary axon pathway; (H) Cer treated GFP-labeled NBT mutant zebrafish 
showing primary axon pathway. 
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Fig. 4.7-A 
 
 
Fig. 4.7-B 
Figure Contd… 
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Fig. 4.7-C 
 
Fig. 4.7-D 
Figure Contd… 
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Fig. 4.7-E,F,G 
 
was also confirmed using GFP labeled NBT transgenic fish showing an early branching in the 
mid-somite region (Figure 4.8-B) compared to DMSO treated transgenic fish (Figure 4.8-A). 
4.4 Conclusion 
Our results show that ceramide was anti-angiogenic as confirmed by both the CAM assay 
as well as zebrafish model. SPM proved to facilitate sprouting, however, the blood vessels 
looked dilated. GlcCer, disrupted the neovascularization in the CAM model and restricted the 
ISV formation in zebrafish. These results, based on the repeatability of the experiment and the 
number of embryos treated during our study, establishes the role of Cer as an anti-angiogenic 
bioactive agent. However, the role of SPM and GlcCer in angiogenesis needs to be further 
investigated to confirm these initial observations. Taken together with its already proven role as 
a pro-apoptotic agent, Cer could serve as an extremely potent chemopreventive bioactive 
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Figure 4.8 GFP-labeled  Primary Motor Neurons of Transgenic Zebrafish. 
A. DMSO treated zebrafish; B. Cer treated zebrafish 
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compound from a dietary source. The role of ceramide in axonal genesis and pathfinding is also 
worth consideration as our experiments have demonstrated its effect on the axon guidance. It can 
be readily interpreted that Cer participates in vasculature as well as neuronal growth and/or axon 
guidance.  
 Our results are in agreement with the recent studies on the factors that guide growth cone 
extensions that can also regulate migration of putative angioblasts. It has been demonstrated that 
VEGF, which regulates migration of angioblast, is also involved in axonal pathfinding (Shoji et 
al., 2003). Recent studies on glycoproteins such as neuropilin-1 (NRP1) and neuropilin-2 
(NRP2) have been implicated in regulating both semaphorins in neuronal guidance and vascular 
endothelial growth factor (VEGF) in angiogenesis (Negishi et al., 2005). It would be interesting 
to investigate the role of Cer in regulating the levels of guidance factors such as the semaphorins, 
ephrins and nitrins and growth factors such as VEGF, EGF, bFGF. 
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CHAPTER 5.  SUMMARY AND CONCLUSIONS 
Functional foods have gained prominence in recent years. The ability to prevent chronic 
diseases through healthy diet has been of main research focus in the field of food science. Many 
bioactive compounds from food sources have been proven to be beneficial to humans. Prevention 
of degenerative diseases through diet now is considered to be a viable strategy. In keeping with 
the research focus in our mind, we set forth to assess the bioactive compounds of milk source 
against cancer. Our hypothesis was to test the efficacy of a group of compounds called 
sphingolipids found in many foods of plant and animal origin. Milk being the highest source of 
sphingolipids, based on the consumption per capita in US, we used the sphingolipids of milk 
source as our compounds of interest. The effect of these compounds on cancer proliferation and 
its growth assisted by angiogenesis was accessed. Angiogenesis plays an important role in tumor 
growth initiated by growth factors expressed by tumor which leads to formation if new blood 
vessels to the tumor. Tumors are generally under the influence of hypoxia and require oxygen 
and nutrients in order to grow.   Hypoxic environment leads to the expression of Hypoxia 
inducing factors (HIF) which further promotes expression of angiogenic growth factors such as 
VEGF which initiates new blood vessel sprouting. The newly formed blood vessels supply 
oxygen and nutrient to the tumor which aids in its proliferation and subsequently helps in 
localization of cancer to other parts of the body, called as metastasis. Therefore, preventing the 
formation of new blood vessels can serve as an approach to inhibit tumor from proliferation. 
Angiogenesis can be inhibited by various anti-angiogenic compounds which can inhibit growth 
factors such as VEGF, bFGF and EFG etc. 
We investigated the effect of sphingolipids using in vitro techniques using cancer cell-
lines. We also examined the anti-angiogenic activity of sphingolipids on the expression of 
angiogenic biomarkers such as VEGF. The ability of the cancer cells to migrate under the 
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influence of sphingolipids was also studied by conducting cells migration assays. Further, the 
effect of sphingolipids on cancer metastasis was accessed by testing the levels of cathepsin-D in 
the cancer cells exposed to the compounds. Response of the cancer cell to sphingolipids under 
the influence of hypoxia was determined by measuring the levels of hypoxia inducing factors 
such as HIF-1α subunit. 
The in vivo study was conducted using chic chorioallantoic membrane vessel (CAM) 
assay and zebrafish model system. As zebrafish serves as a models system for developmental 
biology and is a novel system for studying the motor neuron and vasculature patterning during 
embryo genesis, we investigated how sphingolipids would simultaneously affect the process of 
angiogenesis as well as motor neuron axon guidance. 
For normal lung cells (HEL 299), Cer seemed to be proliferative with high VEGF 
expression and also high cathepsin-D, but low cell migration. SPM had static growth with no 
significant difference in VEGF expression and low levels of cathepsin-D expression and low cell 
migration. GlcCer had lower proliferation with no significant VEGF expression. However, there 
was lower cathepsin-D and reduced cell migration. Breast cancer MCF-7 cells treated with Cer 
had a significant effect on the cell death at higher concentrations with lower VEGF expression 
compared to GlcCer and SPM. The levels of cathepsin-D were higher. The cell migration was 
similar under normoxic conditions but was reduced under hypoxic conditions. SPM had a 
proliferative effect on MCF-7 cell lines under normoxic conditions but there was no significant 
difference under hypoxic conditions. Cathepsin-D expression was significantly lower under both 
conditions. However, cell migration remained unchanged. GlcCer had a proliferative effect under 
normoxic conditions on MCF-7 cells but had significant apoptotic activity under hypoxic 
conditions. Also, the cathepsin-D and HIF-1α were significantly reduced under hypoxic  
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conditions. The levels of VEGF and cell migration remained unchanged when compared to 
control. 
Colon cancer cells (Caco-2) treated with Cer had increased proliferation under 
concentrations < 50 μM but had reduced cell growth at > 50 μM under normoxic as well as 
hypoxic conditions. VEGF expression was greatly increased under the influence of Cer in 
hypoxic condition. However, cathepsin-D, cell migration and HIF-1α were significantly reduced 
under hypoxic conditions. SPM resulted in arrested cell growth under the concentrations studied 
in normoxic and hypoxic conditions with low cathepsin-D levels, cell migrations in normoxic 
and hypoxic conditions as well as low HIF-1α at hypoxic condition. GlcCer increased the cell 
viability with increased VEGF expression under both conditions and caused no significant 
difference in HIF-1α expression under hypoxic conditions. The levels of cathepsin-D expression 
and cell migration were reduced under normoxic as well as hypoxic conditions. 
Prostate cancer cells (DU-145) exposed to Cer and GlcCer had greater cell viability at 
high concentration (> 30 μM) while SPM reduced cell viability. All the compounds caused lower 
levels of VEGF expression at normoxic conditions with 50 μM exposure; only GlcCer had lower 
VEGF expression under hypoxic condition. Cathepsin-D exposure was significantly reduced 
under both conditions for SPM and GlcCer treatments. The cell migration was reduced under 
normoxic condition and also for cells exposed to Cer under hypoxic condition. The HIF-1α was 
significantly reduced in all the compounds treated. 
The C6-ceramide tested in the chicken CAM affected blood vessels within 24 h and SPM 
caused significant vasculature growth, but the vessels looked dilated and newly formed vessels 
were seen sprouting from the Aorta within 24h of exposure. GlcCer regressed the formation of a 
large number of vessels.  Zebrafish treated with Cer had a distinctive loss of blood flow at 48 hpf 
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compared to the controls treated with 0.8% DMSO. SPM proved to facilitate aberrant blood flow 
through ISVs; however, the blood vessels looked dilated at choicepoint in the mid-trunk region. 
The survival rate in SPM treated embryos was 83%. GlcCer constricted the ISV formation in 
zebrafish when observed between 48-80 hpf with a mortality of 80%. C6-Ceramide treated 
embryos had aberrant motor neuron axon trajectories with MiP and CaP motor axons developing 
ectopic branches at the region of the choice point dorsally and ventral somite region respectively. 
The overall in vitro results suggests that ceramide was effective against MCF-7 cell lines 
under normoxic as well as hypoxia induced conditions. Sphingomyelin was effective against 
Caco-2 and DU-145 cancer cell-lines treated under normoxic conditions. Sphingomyelin was 
also effective in reducing the levels of VEGF, Cathepsin D and HIF-1α under hypoxia induced 
environment. Glucosylceramide was specifically effective on DU-145 cell-lines under both 
normoxic as well as hypoxia induced conditions. In vivo studies conclude the activity of 
ceramide and glucosylceramide in inhibiting the vasculature patterning both by CAM assay and 
Zebrafish analysis. Also, ceramide was proven to affect the motor neuron axon guidance 
simultaneous as determined using zebrafish model system. The results therefore validate the 
potential of sphingolipids from milk-source as anti-angiogenic compounds.  
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APPENDIX A: SAS POST-HOC ANALYSIS 
 
Cell Migration 
HEL 299 
Testing the effect of compounds on cell migration of cancer cell lines      10 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square             97.1764 
Critical Value of t           2.77645 
Least Significant Difference    27.37 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
control - glu            43.525      16.155   70.895  *** 
control - cer            50.180      22.810   77.550  *** 
control - spm            80.910      53.540  108.280  *** 
glu     - control       -43.525     -70.895  -16.155  *** 
glu     - cer             6.655     -20.715   34.025 
glu     - spm            37.385      10.015   64.755  *** 
cer     - control       -50.180     -77.550  -22.810  *** 
cer     - glu            -6.655     -34.025   20.715 
cer     - spm            30.730       3.360   58.100  *** 
spm     - control       -80.910    -108.280  -53.540  *** 
spm     - glu           -37.385     -64.755  -10.015  *** 
spm     - cer           -30.730     -58.100   -3.360  *** 
 
 
MCF-7 Normoxic 
Testing the effect of compounds on cell migration of cancer cell lines      11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
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Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            170.8516 
Critical Value of t           2.77645 
Least Significant Difference   36.291 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between     95% Confidence 
   Comparison             Means         Limits 
 
control - spm              2.89     -33.41   39.18 
control - glu              9.41     -26.88   45.70 
control - cer             11.39     -24.90   47.68 
spm     - control         -2.89     -39.18   33.41 
spm     - glu              6.52     -29.77   42.82 
spm     - cer              8.50     -27.79   44.80 
glu     - control         -9.41     -45.70   26.88 
glu     - spm             -6.52     -42.82   29.77 
glu     - cer              1.98     -34.31   38.27 
cer     - control        -11.39     -47.68   24.90 
cer     - spm             -8.50     -44.80   27.79 
cer     - glu             -1.98     -38.27   34.31 
 
 
MCF-7 Hypoxic 
Testing the effect of compounds on cell migration of cancer cell lines      11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            162.4459 
Critical Value of t           2.77645 
Least Significant Difference   35.387 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between     95% Confidence 
   Comparison             Means         Limits 
 
glu     - spm              3.80     -31.59   39.18 
glu     - control          5.06     -30.33   40.44 
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glu     - cer             39.48       4.09   74.87  *** 
spm     - glu             -3.80     -39.18   31.59 
spm     - control          1.26     -34.13   36.65 
spm     - cer             35.69       0.30   71.07  *** 
control - glu             -5.06     -40.44   30.33 
control - spm             -1.26     -36.65   34.13 
control - cer             34.43      -0.96   69.81 
cer     - glu            -39.48     -74.87   -4.09  *** 
cer     - spm            -35.69     -71.07   -0.30  *** 
cer     - control        -34.43     -69.81    0.96 
 
 
Caco-2 Normoxic 
Testing the effect of compounds on cell migration of cancer cell lines      11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            100.8373 
Critical Value of t           2.77645 
Least Significant Difference    27.88 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between     95% Confidence 
   Comparison             Means         Limits 
 
control - glu             50.16      22.28   78.04  *** 
control - cer             63.25      35.37   91.13  *** 
control - spm             67.11      39.23   94.99  *** 
glu     - control        -50.16     -78.04  -22.28  *** 
glu     - cer             13.09     -14.79   40.97 
glu     - spm             16.95     -10.93   44.83 
cer     - control        -63.25     -91.13  -35.37  *** 
cer     - glu            -13.09     -40.97   14.79 
cer     - spm              3.86     -24.02   31.74 
spm     - control        -67.11     -94.99  -39.23  *** 
spm     - glu            -16.95     -44.83   10.93 
spm     - cer             -3.86     -31.74   24.02 
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Caco-2 Hypoxic 
 
Testing the effect of compounds on cell migration of cancer cell lines      11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            136.3099 
Critical Value of t           2.77645 
Least Significant Difference   32.416 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between     95% Confidence 
   Comparison             Means         Limits 
 
control - glu             42.24       9.82   74.65  *** 
control - cer             48.14      15.72   80.56  *** 
control - spm             64.58      32.17   97.00  *** 
glu     - control        -42.24     -74.65   -9.82  *** 
glu     - cer              5.90     -26.51   38.32 
glu     - spm             22.35     -10.07   54.77 
cer     - control        -48.14     -80.56  -15.72  *** 
cer     - glu             -5.90     -38.32   26.51 
cer     - spm             16.44     -15.97   48.86 
spm     - control        -64.58     -97.00  -32.17  *** 
spm     - glu            -22.35     -54.77   10.07 
spm     - cer            -16.44     -48.86   15.97 
 
 
DU-145 Normoxic 
 
Testing the effect of compounds on cell migration of cancer cell lines      11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
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Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            84.58778 
Critical Value of t           2.77645 
Least Significant Difference   25.535 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
control - spm            38.955      13.420   64.490  *** 
control - cer            52.285      26.750   77.820  *** 
control - glu            91.550      66.015  117.085  *** 
spm     - control       -38.955     -64.490  -13.420  *** 
spm     - cer            13.330     -12.205   38.865 
spm     - glu            52.595      27.060   78.130  *** 
cer     - control       -52.285     -77.820  -26.750  *** 
cer     - spm           -13.330     -38.865   12.205 
cer     - glu            39.265      13.730   64.800  *** 
glu     - control       -91.550    -117.085  -66.015  *** 
glu     - spm           -52.595     -78.130  -27.060  *** 
glu     - cer           -39.265     -64.800  -13.730  *** 
 
 
 
DU-145 Hypoxic 
 
 
Testing the effect of compounds on cell migration of cancer cell lines      11 
 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
 
The GLM Procedure 
 
 
t Tests (LSD) for value 
 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            120.2951 
Critical Value of t           2.77645 
Least Significant Difference   30.452 
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Comparisons significant at the 0.05 level are indicated by ***. 
  
 
                        Difference 
       trt              Between     95% Confidence 
   Comparison             Means         Limits 
 
control - glu              3.93     -26.53   34.38 
control - spm             26.11      -4.34   56.56 
control - cer             39.22       8.76   69.67  *** 
glu     - control         -3.93     -34.38   26.53 
glu     - spm             22.19      -8.27   52.64 
glu     - cer             35.29       4.84   65.74  *** 
spm     - control        -26.11     -56.56    4.34 
spm     - glu            -22.19     -52.64    8.27 
spm     - cer             13.10     -17.35   43.56 
cer     - control        -39.22     -69.67   -8.76  *** 
cer     - glu            -35.29     -65.74   -4.84  *** 
cer     - spm            -13.10     -43.56   17.35
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VEGF Levels 
HEL 299 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            0.000017 
Critical Value of t           2.77645 
Least Significant Difference   0.0114 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between       95% Confidence 
   Comparison             Means           Limits 
 
cer     - spm          0.013000     0.001552  0.024448  *** 
cer     - glu          0.022000     0.010552  0.033448  *** 
cer     - control      0.023000     0.011552  0.034448  *** 
spm     - cer         -0.013000    -0.024448 -0.001552  *** 
spm     - glu          0.009000    -0.002448  0.020448 
spm     - control      0.010000    -0.001448  0.021448 
glu     - cer         -0.022000    -0.033448 -0.010552  *** 
glu     - spm         -0.009000    -0.020448  0.002448 
glu     - control      0.001000    -0.010448  0.012448 
control - cer         -0.023000    -0.034448 -0.011552  *** 
control - spm         -0.010000    -0.021448  0.001448 
control - glu         -0.001000    -0.012448  0.010448 
 
 
MCF-7 Normoxic 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            0.000089 
Critical Value of t           2.77645 
Least Significant Difference   0.0262 
 
Comparisons significant at the 0.05 level are indicated by ***. 
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                     Difference 
       trt              Between       95% Confidence 
   Comparison             Means           Limits 
 
glu     - spm          0.000000    -0.026230  0.026230 
glu     - control      0.006500    -0.019730  0.032730 
glu     - cer          0.026500     0.000270  0.052730  *** 
spm     - glu          0.000000    -0.026230  0.026230 
spm     - control      0.006500    -0.019730  0.032730 
spm     - cer          0.026500     0.000270  0.052730  *** 
control - glu         -0.006500    -0.032730  0.019730 
control - spm         -0.006500    -0.032730  0.019730 
control - cer          0.020000    -0.006230  0.046230 
cer     - glu         -0.026500    -0.052730 -0.000270  *** 
cer     - spm         -0.026500    -0.052730 -0.000270  *** 
cer     - control     -0.020000    -0.046230  0.006230 
 
 
MCF-7 Hypoxic 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            0.000413 
Critical Value of t           2.77645 
Least Significant Difference   0.0564 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
spm     - control       0.00800    -0.04843  0.06443 
spm     - glu           0.02100    -0.03543  0.07743 
spm     - cer           0.03050    -0.02593  0.08693 
control - spm          -0.00800    -0.06443  0.04843 
control - glu           0.01300    -0.04343  0.06943 
control - cer           0.02250    -0.03393  0.07893 
glu     - spm          -0.02100    -0.07743  0.03543 
glu     - control      -0.01300    -0.06943  0.04343 
glu     - cer           0.00950    -0.04693  0.06593 
cer     - spm          -0.03050    -0.08693  0.02593 
cer     - control      -0.02250    -0.07893  0.03393 
cer     - glu          -0.00950    -0.06593  0.04693 
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Caco-2 Normoxic 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square             0.00052 
Critical Value of t           2.77645 
Least Significant Difference   0.0633 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
spm     - glu           0.04150    -0.02182  0.10482 
spm     - cer           0.04950    -0.01382  0.11282 
spm     - control       0.05150    -0.01182  0.11482 
glu     - spm          -0.04150    -0.10482  0.02182 
glu     - cer           0.00800    -0.05532  0.07132 
glu     - control       0.01000    -0.05332  0.07332 
cer     - spm          -0.04950    -0.11282  0.01382 
cer     - glu          -0.00800    -0.07132  0.05532 
cer     - control       0.00200    -0.06132  0.06532 
control - spm          -0.05150    -0.11482  0.01182 
control - glu          -0.01000    -0.07332  0.05332 
control - cer          -0.00200    -0.06532  0.06132 
 
Caco-2 Hypoxic 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            0.000529 
Critical Value of t           2.77645 
Least Significant Difference   0.0639 
 
 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
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                       Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
spm     - glu           0.00700    -0.05688  0.07088 
spm     - cer           0.00850    -0.05538  0.07238 
spm     - control       0.06200    -0.00188  0.12588 
glu     - spm          -0.00700    -0.07088  0.05688 
glu     - cer           0.00150    -0.06238  0.06538 
glu     - control       0.05500    -0.00888  0.11888 
cer     - spm          -0.00850    -0.07238  0.05538 
cer     - glu          -0.00150    -0.06538  0.06238 
cer     - control       0.05350    -0.01038  0.11738 
control - spm          -0.06200    -0.12588  0.00188 
control - glu          -0.05500    -0.11888  0.00888 
control - cer          -0.05350    -0.11738  0.01038 
 
 
DU-145 Normoxic 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            0.004069 
Critical Value of t           2.77645 
Least Significant Difference   0.1771 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
control - spm           0.18650     0.00940  0.36360  *** 
control - cer           0.18750     0.01040  0.36460  *** 
control - glu           0.20500     0.02790  0.38210  *** 
spm     - control      -0.18650    -0.36360 -0.00940  *** 
spm     - cer           0.00100    -0.17610  0.17810 
spm     - glu           0.01850    -0.15860  0.19560 
cer     - control      -0.18750    -0.36460 -0.01040  *** 
cer     - spm          -0.00100    -0.17810  0.17610 
cer     - glu           0.01750    -0.15960  0.19460 
glu     - control      -0.20500    -0.38210 -0.02790  *** 
glu     - spm          -0.01850    -0.19560  0.15860 
glu     - cer          -0.01750    -0.19460  0.15960 
 
DU-145 Hypoxic 
The GLM Procedure 
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t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            0.001583 
Critical Value of t           2.77645 
Least Significant Difference   0.1105 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
control - cer           0.00250    -0.10797  0.11297 
control - spm           0.04000    -0.07047  0.15047 
control - glu           0.08800    -0.02247  0.19847 
cer     - control      -0.00250    -0.11297  0.10797 
cer     - spm           0.03750    -0.07297  0.14797 
cer     - glu           0.08550    -0.02497  0.19597 
spm     - control      -0.04000    -0.15047  0.07047 
spm     - cer          -0.03750    -0.14797  0.07297 
spm     - glu           0.04800    -0.06247  0.15847 
glu     - control      -0.08800    -0.19847  0.02247 
glu     - cer          -0.08550    -0.19597  0.02497 
glu     - spm          -0.04800    -0.15847  0.06247 
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Cathepsin D 
 
HEL 299 
Testing the effect of compounds on VEGF expression on cancer cell lines     11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            8.294888 
Critical Value of t           2.77645 
Least Significant Difference   7.9964 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
cer     - control        10.339       2.343   18.335  *** 
cer     - spm            54.237      46.241   62.234  *** 
cer     - glu            55.932      47.936   63.929  *** 
control - cer           -10.339     -18.335   -2.343  *** 
control - spm            43.898      35.902   51.895  *** 
control - glu            45.593      37.597   53.590  *** 
spm     - cer           -54.237     -62.234  -46.241  *** 
spm     - control       -43.898     -51.895  -35.902  *** 
spm     - glu             1.695      -6.301    9.691 
glu     - cer           -55.932     -63.929  -47.936  *** 
glu     - control       -45.593     -53.590  -37.597  *** 
glu     - spm            -1.695      -9.691    6.301 
 
MCF-7 Normoxic 
Testing the effect of compounds on VEGF expression on cancer cell lines     11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            217.9845 
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Critical Value of t           2.77645 
Least Significant Difference   40.992 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
cer     - control         42.37        1.38    83.37  *** 
cer     - glu             79.66       38.67   120.65  *** 
cer     - spm            106.78       65.79   147.77  *** 
control - cer            -42.37      -83.37    -1.38  *** 
control - glu             37.29       -3.70    78.28 
control - spm             64.41       23.41   105.40  *** 
glu     - cer            -79.66     -120.65   -38.67  *** 
glu     - control        -37.29      -78.28     3.70 
glu     - spm             27.12      -13.87    68.11 
spm     - cer           -106.78     -147.77   -65.79  *** 
spm     - control        -64.41     -105.40   -23.41  *** 
spm     - glu            -27.12      -68.11    13.87 
 
 
MCF-7 Hypoxic 
Testing the effect of compounds on VEGF expression on cancer cell lines     10 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square             174.585 
Critical Value of t           2.77645 
Least Significant Difference   36.685 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
cer     - control         50.85       14.16    87.53  *** 
cer     - glu             57.63       20.94    94.31  *** 
cer     - spm            179.66      142.98   216.35  *** 
control - cer            -50.85      -87.53   -14.16  *** 
control - glu              6.78      -29.91    43.47 
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control - spm            128.81       92.13   165.50  *** 
glu     - cer            -57.63      -94.31   -20.94  *** 
glu     - control         -6.78      -43.47    29.91 
glu     - spm            122.03       85.35   158.72  *** 
spm     - cer           -179.66     -216.35  -142.98  *** 
spm     - control       -128.81     -165.50   -92.13  *** 
spm     - glu           -122.03     -158.72   -85.35  *** 
 
 
Caco-2 Normoxic 
Testing the effect of compounds on VEGF expression on cancer cell lines     11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            58.89442 
Critical Value of t           2.77645 
Least Significant Difference   21.307 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between       95% Confidence 
   Comparison             Means           Limits 
 
cer     - control        28.814        7.506    50.121  *** 
cer     - glu           100.000       78.693   121.307  *** 
cer     - spm           118.644       97.337   139.951  *** 
control - cer           -28.814      -50.121    -7.506  *** 
control - glu            71.186       49.879    92.494  *** 
control - spm            89.831       68.523   111.138  *** 
glu     - cer          -100.000     -121.307   -78.693  *** 
glu     - control       -71.186      -92.494   -49.879  *** 
glu     - spm            18.644       -2.663    39.951 
spm     - cer          -118.644     -139.951   -97.337  *** 
spm     - control       -89.831     -111.138   -68.523  *** 
spm     - glu           -18.644      -39.951     2.663 
 
Caco-2 Hypoxic 
Testing the effect of compounds on VEGF expression on cancer cell lines     11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
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NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            14.88106 
Critical Value of t           2.77645 
Least Significant Difference    10.71 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
cer     - spm            25.424      14.713   36.134  *** 
cer     - glu            28.814      18.103   39.524  *** 
cer     - control        28.814      18.103   39.524  *** 
spm     - cer           -25.424     -36.134  -14.713  *** 
spm     - glu             3.390      -7.321   14.100 
spm     - control         3.390      -7.321   14.100 
glu     - cer           -28.814     -39.524  -18.103  *** 
glu     - spm            -3.390     -14.100    7.321 
glu     - control         0.000     -10.710   10.710 
control - cer           -28.814     -39.524  -18.103  *** 
control - spm            -3.390     -14.100    7.321 
control - glu             0.000     -10.710   10.710 
 
 
 
DU-145 Normoxic 
Testing the effect of compounds on VEGF expression on cancer cell lines     11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            10.31086 
Critical Value of t           2.77645 
Least Significant Difference   8.9153 
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Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
control - glu            27.119      18.203   36.034  *** 
control - cer            62.712      53.797   71.627  *** 
control - spm            75.424      66.508   84.339  *** 
glu     - control       -27.119     -36.034  -18.203  *** 
glu     - cer            35.593      26.678   44.509  *** 
glu     - spm            48.305      39.390   57.220  *** 
cer     - control       -62.712     -71.627  -53.797  *** 
cer     - glu           -35.593     -44.509  -26.678  *** 
cer     - spm            12.712       3.797   21.627  *** 
spm     - control       -75.424     -84.339  -66.508  *** 
spm     - glu           -48.305     -57.220  -39.390  *** 
spm     - cer           -12.712     -21.627   -3.797  *** 
 
DU-145 Hypoxic 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            4 
Error Mean Square            6.988647 
Critical Value of t           2.77645 
Least Significant Difference   7.3398 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
                     Difference 
       trt              Between      95% Confidence 
   Comparison             Means          Limits 
 
control - spm            66.102      58.762   73.442  *** 
control - cer            67.797      60.457   75.136  *** 
control - glu            69.492      62.152   76.831  *** 
spm     - control       -66.102     -73.442  -58.762  *** 
spm     - cer             1.695      -5.645    9.035 
spm     - glu             3.390      -3.950   10.730 
cer     - control       -67.797     -75.136  -60.457  *** 
cer     - spm            -1.695      -9.035    5.645 
cer     - glu             1.695      -5.645    9.035 
glu     - control       -69.492     -76.831  -62.152  *** 
glu     - spm            -3.390     -10.730    3.950 
glu     - cer            -1.695      -9.035    5.645
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HIF Levels 
MCF-7 Hypoxic 
Testing the effect of compounds on HIF expression on cancer cell lines      11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            5 
Error Mean Square            0.000051 
Critical Value of t           2.57058 
Least Significant Difference   0.0183 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                 Difference 
     trt            Between       95% Confidence 
 Comparison           Means           Limits 
 
cntrH - cerH       0.065500     0.047163  0.083837  *** 
cntrH - spmH       0.075500     0.057163  0.093837  *** 
cntrH - gluH       0.084000     0.065663  0.102337  *** 
cntrH - cntrN      0.120000     0.101663  0.138337  *** 
cerH  - cntrH     -0.065500    -0.083837 -0.047163  *** 
cerH  - spmH       0.010000    -0.008337  0.028337 
cerH  - gluH       0.018500     0.000163  0.036837  *** 
cerH  - cntrN      0.054500     0.036163  0.072837  *** 
spmH  - cntrH     -0.075500    -0.093837 -0.057163  *** 
spmH  - cerH      -0.010000    -0.028337  0.008337 
spmH  - gluH       0.008500    -0.009837  0.026837 
spmH  - cntrN      0.044500     0.026163  0.062837  *** 
gluH  - cntrH     -0.084000    -0.102337 -0.065663  *** 
gluH  - cerH      -0.018500    -0.036837 -0.000163  *** 
gluH  - spmH      -0.008500    -0.026837  0.009837 
gluH  - cntrN      0.036000     0.017663  0.054337  *** 
cntrN - cntrH     -0.120000    -0.138337 -0.101663  *** 
cntrN - cerH      -0.054500    -0.072837 -0.036163  *** 
cntrN - spmH      -0.044500    -0.062837 -0.026163  *** 
cntrN - gluH      -0.036000    -0.054337 -0.017663  *** 
 
 
Caco-2 Hypoxic 
Testing the effect of compounds on HIF expression on cancer cell lines      11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
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t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            5 
Error Mean Square             0.00004 
Critical Value of t           2.57058 
Least Significant Difference   0.0162 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                 Difference 
     trt            Between       95% Confidence 
 Comparison           Means           Limits 
 
cerH  - cntrH      0.000000    -0.016243  0.016243 
cerH  - cntrN      0.012000    -0.004243  0.028243 
cerH  - gluH       0.012500    -0.003743  0.028743 
cerH  - spmH       0.060500     0.044257  0.076743  *** 
cntrH - cerH       0.000000    -0.016243  0.016243 
cntrH - cntrN      0.012000    -0.004243  0.028243 
cntrH - gluH       0.012500    -0.003743  0.028743 
cntrH - spmH       0.060500     0.044257  0.076743  *** 
cntrN - cerH      -0.012000    -0.028243  0.004243 
cntrN - cntrH     -0.012000    -0.028243  0.004243 
cntrN - gluH       0.000500    -0.015743  0.016743 
cntrN - spmH       0.048500     0.032257  0.064743  *** 
gluH  - cerH      -0.012500    -0.028743  0.003743 
gluH  - cntrH     -0.012500    -0.028743  0.003743 
gluH  - cntrN     -0.000500    -0.016743  0.015743 
gluH  - spmH       0.048000     0.031757  0.064243  *** 
spmH  - cerH      -0.060500    -0.076743 -0.044257  *** 
spmH  - cntrH     -0.060500    -0.076743 -0.044257  *** 
spmH  - cntrN     -0.048500    -0.064743 -0.032257  *** 
spmH  - gluH      -0.048000    -0.064243 -0.031757  *** 
 
 
DU-145 Hypoxic 
Testing the effect of compounds on HIF expression on cancer cell lines      11 
 
ANOVA with SAS PROC GLM with post hoc and HOV tests 
 
The GLM Procedure 
 
t Tests (LSD) for value 
 
NOTE: This test controls the Type I comparisonwise error rate, not the 
experimentwise error rate. 
 
 
Alpha                            0.05 
Error Degrees of Freedom            5 
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Error Mean Square            0.000062 
Critical Value of t           2.57058 
Least Significant Difference   0.0203 
 
 
Comparisons significant at the 0.05 level are indicated by ***. 
 
 
                 Difference 
     trt            Between       95% Confidence 
 Comparison           Means           Limits 
 
cntrH - gluH       0.073000     0.052748  0.093252  *** 
cntrH - spmH       0.081500     0.061248  0.101752  *** 
cntrH - cntrN      0.082500     0.062248  0.102752  *** 
cntrH - cerH       0.091500     0.071248  0.111752  *** 
gluH  - cntrH     -0.073000    -0.093252 -0.052748  *** 
gluH  - spmH       0.008500    -0.011752  0.028752 
gluH  - cntrN      0.009500    -0.010752  0.029752 
gluH  - cerH       0.018500    -0.001752  0.038752 
spmH  - cntrH     -0.081500    -0.101752 -0.061248  *** 
spmH  - gluH      -0.008500    -0.028752  0.011752 
spmH  - cntrN      0.001000    -0.019252  0.021252 
spmH  - cerH       0.010000    -0.010252  0.030252 
cntrN - cntrH     -0.082500    -0.102752 -0.062248  *** 
cntrN - gluH      -0.009500    -0.029752  0.010752 
cntrN - spmH      -0.001000    -0.021252  0.019252 
cntrN - cerH       0.009000    -0.011252  0.029252 
cerH  - cntrH     -0.091500    -0.111752 -0.071248  *** 
cerH  - gluH      -0.018500    -0.038752  0.001752 
cerH  - spmH      -0.010000    -0.030252  0.010252 
cerH  - cntrN     -0.009000    -0.029252  0.011252 
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APPENDIX C: SUPPLEMENT DATA 
 
Supplemental Movies of Zebrafish Sphingolipid Exposure during Embryogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Movie 1: Videomicrograph of Circulation of the Mid-trunk of a 48 hpf DMSO Treated Zebrafish 
Embryo.  
Anterior is to the right, dorsal is up. Blood flows caudally (to the left) via the dorsal aorta (DA) 
and return rostrally (to the right) via posterior cardinal vein (PCV) aligned near intersomitic 
boundaries carry blood dorsally through intersegmental arteries and ventrally through 
intersegmental veins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Movie 2: Videomicrograph of Circulation of the Mid-trunk of a 48 hpf Ceramide Treated 
Zebrafish Embryo.  
Anterior is to the right, dorsal is up. Blood flows caudally (to the left) via the dorsal aorta (DA) 
and return rostrally (to the right) via posterior cardinal vein (PCV) aligned near intersomitic 
boundaries carry blood dorsally through intersegmental arteries and ventrally through 
intersegmental veins. 
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Movie 3: Videomicrograph of Circulation of the Mid-trunk of a 48 hpf Ethanol Treated 
Zebrafish Embryo.  
Anterior is to the left, dorsal is up. Blood flows caudally (to the right) via the dorsal aorta (DA) 
and return rostrally (to the left) via posterior cardinal vein (PCV) aligned near intersomitic 
boundaries carry blood dorsally through intersegmental arteries and ventrally through 
intersegmental veins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Movie 4: Videomicrograph of Circulation of the Mid-trunk of a 48 hpf Sphingomyelin Treated 
Zebrafish Embryo.  
Anterior is to the left, dorsal is up. Blood flows caudally (to the right) via the dorsal aorta (DA) 
and return rostrally (to the left) via posterior cardinal vein (PCV) aligned near intersomitic 
boundaries carry blood dorsally through intersegmental arteries and ventrally through 
intersegmental veins. 
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Movie 5: Videomicrograph of Circulation of the Mid-trunk of a 52 hpf DMSO Treated Zebrafish 
Embryo.  
Anterior is to the right, dorsal is up. Blood flows caudally (to the left) via the dorsal aorta (DA) 
and return rostrally (to the right) via posterior cardinal vein (PCV) aligned near intersomitic 
boundaries carry blood dorsally through intersegmental arteries and ventrally through 
intersegmental veins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Movie 6: Videomicrograph of Circulation of the Mid-trunk of a 52 hpf Glucosylceramide 
Treated Zebrafish Embryo.  
Anterior is to the left, dorsal is up. Blood flows caudally (to the right) via the dorsal aorta (DA) 
and return rostrally (to the left) via posterior cardinal vein (PCV) aligned near intersomitic 
boundaries carry blood dorsally through intersegmental arteries and ventrally through 
intersegmental veins. 
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